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Abstract 
This honours project is based on the advancement of in situ hybridisation to 
metaphase chromosome spreads. The technique was carried out using cosmid probes 
which are specific for microdeleted regions on chromosome 22q 11 associated with 
Di George syndrome (DGS) and related disorders. Disorders similar to DGS include 
partial Di George syndrome, III-IV pha_ryngeal pouch syndrome, velucardiofacial 
syndrome (VCFS), conotruncal facial anomaly and the CHARGE association. 
Recently the group of disorders with this microdeletion and comparable symptoms 
has been summarised by the acronym CATCh 22. 
Large deletions, translocations, monosomies, and trisomies of chromosome·!i are 
apparent under the light microscope, when prepared as metaphase chromosome 
spreads for karyotyping. Subtle microdeletions, however, are seldom detected by 
this method, even when high resolution banding techniques are undertaken. A more 
suitable technique for the detection of such microdeletions is in situ hybridisation. In 
situ hybridisation (ISH) has successful!y been employed to identifY chromosomes, to 
detect chromosomal abnormalities, and to determine chromosomal locations of 
specific gene sequences. The aim of the present study is to apply in situ 
i hybridisation to the detection of suspected microdeletions of chromosome 22qll. 
Fluorescent in situ hybridisation (FISH) and other forms of non-isotopic in situ 
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hybridisation (NISH) were carried out with cosmid probes specif..c for chromosome 
region 22qll, on peripheral blood samples of patients displaying DGS-like 
symptoms and controls. Patients suspected of having n: George syndrome were 
surveyed by Dr. S. Worthington at Princess Margaret Hospital for Children (Western 
Australia) as part of a clinical study into familial congenital heart disease (CHD). 
All patients tested have CHD, and display some DGS-like symptoms. The 
advancement of the FISH technique will assist clinicians in the identification of 
patients with the CATCH 22 sequence, and will further serve to demonstrate the 
ability of a cosmi.d probe to detect a microdeletion associated with a clinical 
disorder. The effectiveness of the method will also be compared to results obtained 
by routine cytogenetic analysis. The study shows that although in situ hybridisation 
is technically difficult to establish, it holds great promise as a sensitive and specific 
diagnostic test and research tool. 
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L...Literature Reyiew 
1.1 Introduction 
Di George syndrome (DGS) is a developmental field defect of the third and fourth 
brachial arches. It was first described by Angelo Di George (1968), and since that 
time numerous clinical, cytogenetic and molecular studies have been undertaken to 
identifY the spectrum of associated defects (Greenberg eta/., 1988a). The clinical 
features, which are diverse and vary in severity, include congenital heart disease 
(CHD) such as tetralogy of Fallot, interrupted aortic arch, ventricular septal defects 
and hypocalcaemia, facial abnormalities and a poor immune system due to the 
absence of the thymus. Most patients have evidence of CHD but some may present 
only with hypocalcaemic seizures (Conley eta/., 1979). The first recorded familial 
cases of DGS were associated with an unbalanced chromosome 20:22 translocation, 
which resulted in monosomy 22qll (De Ia Chapelle eta/., 1981). The ability to 
detect monosomy 22q II is questionable with routine cytogenetic analysis (Desmaze 
et a/., 1993a). The microdeletion which is thought to be responsible for DGS, 
however, can be more readily detected by non-isotopic in situ hybridisation (NISH), 
particularly fluorescent in situ hybridisation (FISH) (Carey eta/., 1992). In FISH the 
cosmid probe DNA is hybridised to its complementary sequence of chromosomal 
DNA, on the particular chromosome where that sequence is found. The cosmid 
probe which is used to detect the deletion associated with DGS corresponds to a 
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region on chromosome 22q 1 L In FISH the probe DNA is labelled with a 
fluorochrome to facilitate detection, and the chromosomes are visualised with an 
appropriate counterstain. If fluorescein, a yellow-green fluorochrome, is used to 
label the probe then propidium iodide is· applied as the counterstain. The resultant 
red-stained metaphase chromosomes are then viewed under fluorescent microscopy, 
the hybridisation signal which highlights the chromosome-probe hybrid fluoresces as 
a bright yellow signal. In situ hybridisation has been used to detect the presence of 
many clinical disorders which localise to specific chromosome regions. This 
detection method plays an important role in a variety of research areas, including 
cytogenetics, tumour biology, gene amplification, gene mapping and also in prenatal 
diagnosis (Trask, 1991 ). 
1.2. The hjstocy ofDi George syndrome 
DOS is named after Angelo Di George, an American clinician, who commenced 
research into congenital absence of the thymus in 1963 (Di George, 1968). 
However, he probably was not the first person to note the disorder. A journal article 
from as early as 1829 by H. Harrington described symptoms similar, if not identical, 
to those associated with DGS (Greenberg, 1993). Absence of thymic tissue is also 
often associated with loss of the parathyroid glands, or their ectopic placement, and 
has resulted in DGS-like symptoms (Lobdell, 1959). The major presenting 
symptoms which allow a provisional diagnosis of the disorder are CHD (De Ia 
Chapelle eta/., 1981) and malformations of the palr'1. In DOS patients these are 
•· 
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accompanied by a grossly depressed Cell mediated immunity caused by the absence 
of the thymus (Greenberg, 1993). During infancy hypocalcaemic seizures are caused 
by absence of parathyroids. 
1.3. CHnica1 features ofDi George Syndrome 
Di George syndrome (DGS) consists of varying combinations and degrees of 
hypoparathyroidism, thymic hypoplasia with T-lymphocyte deficiency, congenital 
heart disease (CHD), and dysmorphic facies (Winter et al., 1984). Although the 
symptoms vary in severity, almost all cases result f ~. a detectable deletion within 
chromosome 22qll (Wilson, D. eta/., 1993b). The array of clinical symptoms 
which make up DGS has been summarised by the acronym 'CATCH 22 syndrome'. 
This acronym represents the clinical features (Cardiac, Abnonnal facies, Thymic 
hypoplasia, Cleft palate, and Hypocalcaemia) and chromosome 22 (Wilson, D. eta/., 
1993b). CATCH 22 also suggests the complexity which exists with regard to 
definition of the clinical features, and understanding the genetic ramifications of a 
deletion from a specific area on a particular chromosome (Hall, 1993). 
DGS does not, as its title would suggest, have a set of symptoms which are common 
to all patients. For this reason DGS and other similar syndromes have been classed 
as 'contiguous gene syndromes' (Schrnickel, 1986). Owing to these varying 
symptoms, it has been said of DGS that it probably is not a distinct syndrome of 
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5 
single gene origin but rather an anomaly caused by a heterogeneous developmental 
field defect (Stevens eta/., 1990). 
Due to the variance of symptoms and their possible causes the disease has been given 
several names. The disorder associated with microdeletion 22ql I has not only been 
known as DGS, but also as lll-lV pharyngeal pouch syndrome and partial Di George 
syndrome (Lischner eta/., 1972). Reported cases of partial DGS include apparently 
balanced and unbalanced translocations. A balanced translocation t(2;22) 
(ql4.l;qll.l) was observed in a girl with some, but not all, of the features ofDGS. 
The same translocation was present in the girl's mother and maternal aunt. The latter 
female had her fourth pregnancy aborted due to cardiac and other malformations 
which were detected by ultrasound. The karyotypes of individuals in the family 
show that this particular translocation can be associated with partial DGS, however 
the fetus which was aborted had a much more severe (complete) form of DGS 
(Augusseau eta/., 1986). 
1.4. DQS as a conti~:uous gene syndrom~ 
The heterogeneity of symptoms within families is often associated with contiguous 
gene syndromes, which can be grouped into those with detectable chromosomal 
detects and those without any identifiable aberration at a cytogenetic level (Emanuel, 
1988). One of the forms ofDGS which has been shown to have a translocation at the 
cytogenetic level is partial DGS, a disorder that has been noted in many families. 
Greenberg et a/., (1984) reported a family in which both siblings had DGS 
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phenotype. This phenotype was associated with an unbalanced 4;22 translocation in 
the younger child, which resulted in partial monosomy of chromosome 22qll. The 
o!Jer sibling was deceased and no cytogenetic analysis had been carried out. 
Autopsy revealed that the first sibling had Type I truncus arteriosus, thymic aplasia, 
and parathyroid hypoplasia, the second sibling also had Type I truncus arteriosus 
accompanied by dysmorphic features and T -cell abnonnalities. The mother of both 
children had no history of heart munnur, seizures, or serious infections, although on 
physical examination she did have slightly dysmorphic facies and an identical 
translocation to her younger child. This study provides further evidence that, in 
some individuals, even when DGS is not obvious a microdeletion of 22qll may be 
present (Greenberg eta/., 1984). 
DGS is also closely related to Shprintzen syndrome (also known as velo-cardio-
facial syndrome, VCFS) (Wilson et a/., 1992b), and the CHARGE association 
(Cyran eta/., 1987). It has been surmised that VCFS is caused by a deletion of the 
same gene or set of genes as DGS (Scambler, 1993). It has also been proposed that 
not only do autosomal dominant DGS and VCFS have a common microdeletion, but 
they are in fact all cases ofVCFS (Stevens eta/., 1990). 
1,5, Yelocardiofacial syndrome (YCFS) 
Velocardiofacial syndrome (VCFS) is a syndrome of multiple anomalies, including 
cleft palate, heart malfonnations, facial characteristics and learning disabilities. It 
I j \ 
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was described in a group of 12 unrelated children by Robert Shprintzen in 1978, 
although a familial case had been described previously (Strong, 1978). Since that 
time Shprintzen has examined over 100 affected individuals and has documented the 
phenotypes of all these cases (Goldberg eta/., 1993). Shprintzen has proposed that 
most reported cases of familial DGS are in fact misdiagnosed VCFS (Shprintzen, 
!994), a belief which may be justified given the phenotypic variability of VCFS. 
,j Like DGS, there is considerable phenotypic variability not only between unrelated 
patients but also within families (Holder eta/., 1993). Molecular studies of VCFS 
' 
·-.1 
' 
patients have shown that like DGS they also display monosomy for a region of 
chromosome 22qll (Kelly eta/., 1993). Monosomy 22qll was revealed in 18 
I 
I patients with different probes specific for 22qll, using dosage analysis in search of 
monosomy at this locus. The patients tested in this study disPlayed variable 
phenotypes, although they had all been previously clinically diagnosed as having 
VCFS (Motzkin et a/., 1993). Other studies have also noted extreme clinical 
variability in VCFS patients and Meinecke et a/. (I 986) concluded that VCFS is 
probably caused by a dominant gene with very variable expression. As a result of 
this variability, patients who do not exhibit obvious symptoms, such as cardiac 
defects, may not be • ·erectly diagnosed. One clinical study into VCFS surveyed 38 
children, all of whom were diagnosed as having the disorder, even though 42% of the 
children had no congenital heart defect. It must be noted, however, that no 
cytogenetic or molecular analyGis was reported for this group. It has been suggested 
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therefore that lack of cardiac defect should not deter the clinician from making a 
diagnosis ofVCFS (Lipson eta/., 1991). 
There is no dispute that VCFS and DGS share an aetiological connection. They both 
display evidence of monosomy 22qll and have some common phenotypic fea.,Jres 
(Scarobler eta/., 1992). Due to the overlap in symptoms, some if not all cases of 
DGS may be misdiagnosed cases of VCFS (Goldberg et a/., 1985). Some distinct 
clinical features which are specific to VCFS are not found in DGS (Driscoll et a/., 
1992b), also some researchers see DGS as a particular form of VCFS and not a 
separate disordei. There have been reported cases for example, of psychosis 
associated with VCFS which is not apparent in DGS (Dunharo, et a/., 1992) 
(Shprintzen eta/., 1992). Based on this evidence, DGS may be a particular form of 
VCFS, however many clinicians believe that it can be diagnosed separately from 
VCFS because of its particular combination of symptoms. 
1.6. Possible causes ofDGS 
Although the title of this condition (or conditions) has been a matter of dispute 
(Lischner, 1972), it is widely agreed that the characteristic phenotype ofDGS is the 
result of an abnormality in the formation of the III & IV pharyngeal pouches. An 
embryological disorder of this nature, due to inadequate neural crest contribution in 
development, is termed a neurocristopathy (Hong, 1991). When the DGS 
neurocristopathy was examined it was apparent that a number of events could occur 
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during early pregnancy to cause the condition. As well as chromosomal 
abnormalities, teratogens such as retinoic acid (a synthetic fonn of vitamin A found 
in acne treatments), have been linked to DGS (Lammer eta/., 1985). It has also been 
J 
' 
' 
suggested that maternal insulin dependent diabetes acts as a pathogenetic factor in 
the Di George anomaly. Two infants born to diabetic mothers had apparent DGS }' 
and renal agenesis. Both mothers and their infants had normal cytogenetic 
karyotypes. Molecular studies, using a probe which is believed to be specific for the 
gene region deleted in DGS, failed to detect a microdeletion of chromosome 22qll 
in these patients (Wilson, T. eta/., 1993). 
') 
. 
·.\': 
h· 
DGS is referred to by many researchers as Di George anomaly rather than syndrome, 
the term anomaly being preferred because it infers the numerous suggested 
aetiologies associated with the disorder and stresses its origin as a developmental 
field defect (Opitz & Lewin, 1987). It should be noted that unless DGS and Di 
George anomaly are specifically distinguished from each other, essentially they can 
F':· 
be regarded as the same condition. 
1,7. The variability of conlolenital heart defects (CHD) in DGS 
Genetic defects are known to be a major cause of heart malformation (Wilson et al., 
1991). In DGS and VCFS certain types ofCHD are over-represented by comparison 
with their incidence in the general population (Worthington, 1994). Conotruncal 
cardiac defects are over-represented in both DGS and VCFS. The conotruncal 
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defects particular to DGS are interrupted aortic arch (type B) (JAA), truncus 
arteriosus (TA), and tetralogy ofFallot (TOF). TOF is also one of the most common 
forms of cardiac defect present in VCFS. Since DGS and VCFS have both been 
associated with microdeletions of chromosome 22qll, it was supposed that a 
deletion in the 22ql I region was also responsible for the types of cardiac defect 
common to these disorders. A study to substantiate this assumption was carried out 
on a group of patients with the tetralogy of Falla! defect, who had no other signs of 
either DGS or v'CFS. A total of seventeen patients were tested for evidence of a 
microdeletion in chromosome 22qll using restriction fragment length polymorphism 
(RFLP) and dosage analysis, five of the seventeen were shown to have a 22qll 
deletion (Goldmuntz eta/., I993). As well as RFLP and dosage analysis to test for 
this deletion, Goldmuntz et a/. (1993) also reported on the usefulness of FISH as a 
way to determine whether families with a history of CHD have the 22q II 
microdeletion. Families who have a known deletion, even if unaccompanied by 
symptoms of DGS or VCFS, will be able to utilise clinical testing and genetic 
counselling to determine the risk of heritability of the deletion which accompanies 
CHD. 
Other studies have provided similar evidence on the connection between isolated 
heart defects and the 22ql I microdeletion. DGS was diagnosed in an infant with 
IAA, hypoparathyroidism and low T-cell lymphocyte numbers. Two siblings had 
heart defects that are not common to DGS (a membranous ventricular septal defect, 
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and coarctation of the aorta) and neither sibling showed signs ofDGS. Chromosome 
analysis of their mother, whose cardiovascular examination was nonnal, and her 
three offspring with heart defects all revealed a 22q II interstitial deletion. The 
deletion was subsequently confirmed by molecular analysis (Wilson eta/., 1991). 
This case promoted further study into deletions in nine families with recurrent 
outflow-tract heart defects. In five of the families, chromosome 22 deletions were 
detected in all of the living affected individuals, and they were also present in the 
clinically normal father of a further fr :.1ily in which there were three affected 
children. As a result of these studies it was proposed that deletions within band qll 
of chromosome 22 are an important cause of some familial heart defects (Wilson et 
a/., 1992a). 
1.8 Prenatal detection ofCHD 
Congenital heart defects are often diagnosed prenatally by ultrasound, and it is 
normal to follow the detection of a CHD with prenatal karyotyping in order to 
determine the extent of chromosomal involvement. It has been revealed by such 
karyotyping that chromosome abnormalities are present in 15.4% of fetuses with an 
isolated cardiac malformation and in 42.7% with an additional malformation 
(Catherine eta/., 1991). In children with DGS chromosome abnormalities can prove 
difficult to diagnose prenatally due to the failure of fetal blood to culture for 
karyotyping. This is because individuals with DGS have a reduced number of T-
lymphocytes, and since lymphocytes are the cells cuitured for karyotyping 
- ., '· ' ...... 
12 
insufficient numbers may be available to analyse for a karyotype. It has been 
proposed that if a fetal blood culture cannot be karyotyped when a CHD of the DGS-
type is present, then fetal lymphocyte sub populations should be examined in order to 
diagnose DGS (Catherine eta/., 1991). Although it also has been suggested that, 
when a CHD is diagnosed prenatally, cytogenetic and molecular analysis of amniotic: 
fluid cells or chorionic villi would be more sensitive and accurate than 
characterisation of fetal lymphocyte populations (Driscoll et a/., 1991). It was 
subsequently confirmed that FISH of cultured amniocytes provided an efficient and 
direct method for the pre-natal detection of microdeletions including monosomy 
22q 11, which was detected in two separate pregnancies by this method (Drisco11 et 
a/., 1993). 
Karyotyping of chorionic villi in a family with a known reciprocal balanced 
translocation involving chromosomes 9 and 22, at the regions q22 and ql 1.2 
respectively, revealed an unbalanced karyotype in the fetus. This arose due to an 
adjacent-2 disjunction of the quadrivalent in the mother. The test was performed 
because a previous sibling had died at age three weeks due to cardiovascular 
complications. Karyotyping of this infant revealed the same unbalanced 
translocation as had previously been found in the fetus (Pivnick et a/., I 990). 
Another case where an unbalanced translocation of chromosomes 9;22 was reported 
also resulted in symptoms ofDGS (El-Fouly eta/., 1991). 
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1.9 Prevalence ofDi Georce syndrome 
The number of children affected by DGS is not readily calculated. The prevalence 
has been estimated at I in 20,000, but this figure is probably an under-estimate based 
only on the ascertainment of severe cases (Scambler, I993). If severe and mild cases 
are included then CHD seems to be quite a common disorder with, I in I 00 live 
births resulting in some form of cardiac defect (Hoffman, 1990). In order to gain a 
meaningful insight into the prevalence of DGS, large groups of patients and their 
families will need to be assessed by clinical, cytogenetic and molecular examination. 
The results of such a study will provide not only useful information on the 
prevalence of DOS in the population, but also on the degree of variation in the 
severity of symptoms and their aetiology. 
1,10 The 2enetic aetiology ofDGS 
The genetic aetiology of DOS has been attributed to a microdeletion of chromosome 
22q II, in a region known as the Di George critical region (DGCR). When 
chromosome 22 is deleted in the defined region DOS results. The DOCR was first 
suggested by De !a Chapelle and his colleagues (1981). In their study, a 
chromosome analysis of a large family was undertaken and some members of the 
family were shown to display an unbalanced chromosomal rearrangement leading to 
trisomy 20pter->20qll and monosomy 22pter->22qll. The clinical features of 
trisomy 20p were already known and since they did not correspond to the features of 
•'!. 
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DGS (Francke, 1977), this trisomy was rejected as the cause of DGS. It was 
therefore suggested that DGS was due to a monosomy of the region 22pter--+22qll 
(De Ia Chapelle et a/., 1981). This hypothesis was later verified by cytogenetic 
analysis of other DGS patients with interstitial deletions, del (22)(ql 1.21 ql 1.23) but 
no other apparent cytogenetic abnormality (Greenberg eta/., l988a). 
On the basis of these findings it was hypothesised that the DGCR lies within 22q II 
(Driscoll el a/., l992a). It has subsequently been shown cytogenetically (Wilson et 
a/., 1992b), and by molecular methods (Driscoll et a/., I992a), that most DGS 
patients (approximately 90% as reviewed in Carey el a/., 1992) have a detectable 
22qll microdeletion. This microdeletion is often the result of an unbalanced 
translocation. The specific breakpoint may be important in some cases, however the 
clinical features are probably more related to the activity of the alleles for which the 
patient is hemizygous (Faed eta/., 1987). The modes of inheritance suggested for 
DGS, like that of its symptoms, have been varied. Cases reported to date have most 
often demonstrated an autosomal dominant pattern of inheritance, although 
autosomal recessive and X-linked chromosomal patterns have also been noted 
(Driscoll eta/., l992a). The first reports of autosomal dominant transmission of the 
Di George phenotype were made by De Ia Chapelle (1981 ), and they were 
subsequently verifi•.d by Kelley et al. (1982). The ambiguity which exists with 
regard to the inheritance ofDGS is partly attributable to the difficulty in diagnosing 
a microdeletion. Although parents and siblings may have such a chromosomal 
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aberration, it is quite often missed even when high resolution cytogenetic analysis is 
undertaken (Keppen et a/., 1988). In one family both siblings and their father bad 
evidence of DGS. Their clinical features included hypocalcaemia, unusual facies, 
truncus arteriosus, impaired cell mediated immunity and the father had a relatively 
low number ofT-lymphocytes. Chromosome banding studies nevertheless showed 
ail family members to have normal karyotypes (Rohn eta/., 1984). 
Different chromosome regions have been linked to the phenotypic characteristics of 
DGS other than chromosome 22qll. These aberrations are summarised in Table I.l. 
In spite of the aetiological heterogeneity of DGS, evidence suggests that the most 
common cause is monosomy 22qll (Greenberg, 1993). It has been proposed, 
however, that the DGS gene would be a good model for gene defects which are 
likely to be affected by other genes or environmental influences, as a true polygenic 
or multifactorial disorder. Due to this possible heterogeneity it has been emphasised 
that other DGS loci so far suggested, such as 10pl3, must not be neglected in future 
studies (Greenberg, 1993). 
I. I 1. Cytogenetic analysis of chromosomes 
Human cytogenetic studies are based on the analysis of karyotypes made from 
metaphase chromosome preparations. The earliest recorded attempt to study human 
chromosomes using cultures of leukocytes from peripheral blood was made by 
Chrustchoff and his co-workers in I 931 (Hamerton, I 97 I). 
·''-' 
:··: 
~~-
' 
;· 
\ ..
r 
:;. 
!f/ 
~-'-
f; 
f :-
,f 
r 
• I 
' 
.-; 
: 
' 
.·; 
'' 
... ··,,,,.•_-' 
16 
Table I. I: The less common chromosome aberrations associated with DGS 
Chromosome location Reported by:- Comments 
isochromosome 18q, Clinical signs ofDGS with 
manifests as monosomy van Essen eta/. (I 993) holoprosencephaly and 
I 8p and trisomy I 8q streak ovaries 
Clinical signs of DGS with 
unbalanced paternal Bowen et a/. (I 986) absence of thymus but 
translocation t(I 8;22) involved 22p not 22q 
rnonosomy 12p with Greenberg eta/. (I 988a) Clinical signs ofDGS 
trisomy !Oq 
monosomy 5p Greenberg eta/, (I 988a) Clinical signs of DGS 
partial trisomy I q Greenberg eta/. (I 988a) Clinical signs ofDGS 
monosomy 17p!3 Greenberg eta/. (I 988b) Clinical signs ofDGS 
This chromosomal 
Greenberg eta/. (I 988a) rearrangement has been 
monosomy lOp 13 & associated with DGS 
Monaco et a/. (I 99 I) phenotype on more than 
one occasion 
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It was not, however, untill956 that the chromosome number of humans was verified 
to be 46 (Tjio & Levan, 1956). Even then the available cytogenetic techniques were 
such that it was impossible to clearly distinguish individual chromosomes within a 
particular group. Human metaphase chromosomes can be organised after simple 
staining into seven groups (A-G) according to their relative size and centromeric 
position. Chromosome identification was altered by the advent of quinacrine 
mustard staining (Q-banding) (Caspersson eta/., 1968), which allowed each hmnan 
chromosome pair to be individually recognised. In order to visualise Q~banded 
chromosomes a fluorescent microscope is required. Shortly after the invention of Q-
banding another type of banding technique was discovered, giemsa staining with 
trypsin (G-banding), and tlus type of banding is the preferred method of staining in 
most laboratories. Although, G-banding and Q-banding give similar quality 
karyotypes, G-banding is more common because it is permanent and can be detected 
with a standard light microscope (Harnerton, 1971 ). 
1.12. Production of metaphase chromosome preparations 
Chromosomes analysed by karyotyping are harvested from cultured cells, with a 
droplet of cultured cell suspension fixed on to a microscope slide as a metaphase 
spread. Metaphase spreads are prepared from various specimens such as, peripheral 
blood, amniocytes, chorionic villi, or any tissue or cell line which is actively dividing 
(Verma and Babu, 1989). The specimens are cultured and treated so that the cell 
i 
cycle is arrested at the metaphase stage of mitosis. The cells are then treated with a 
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hypotonic solution Q3mery, 1979). This ensures that on dropping the suspension on 
to a microscope slide the chromosomes in a high proportion of the nuclei will spread. 
The nuclei disperse in such a manner that the chromosomes from each nucleus 
remain distinct from those in adjacent nuclei on the slide. The subsequent 
application of a fixative ensures that the cells adhere to the slide. When the 
metaphase spreads have been fixed to the slides they can then be banded. 
:l 
'• '~ 
-·-~ As previously mentioned, DGS was found to be linked most often with an interstitial 
deletion of22qll (Greenberg eta/., 1988a). Due to the small size of chromosome 
22, standard synchronised G-banded metaphase spreads do not clearly define band 
qll and for this reason it is necessary to produce high resolution preparations in 
order to see a microdeletion in this region. This is achieved by decreasing the time 
that the culture is exposed to colcemid. Colcemid, when added to chromosomes, 
affects spindle fonnation and the chromosomes remain at the metaphase stage of the 
cell cycle. When the chromosomes are exposed to colcemid for a relatively long 
', ' ' 
time they begin to constrict and fewer bands can be defined when stained. By 
' 
' 
reducing colcemid exposure time the chromosomes appear to be longer and more 
bands are produced, which results in suitably high resolution chromosomes (i.e., at 
least 850 bands/haploid set) (Standing Committee on Human Cytogenetic 
Nomenclature, 1985). It has been demonstrated that, even when metaphase spreads 
are prepared at this high resolution, it may still not be possible to locate 
microdeletions cytogenetically (Carey eta/., 1992). If molecular methods are not 
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available, however, it has been suggested that high resolution studies of suspected 
microdeletions are justified, although the number of patients shown to have an 
interstitial deletion by high resolution karyotype may be low (Mascarello el a/., 
1989). 
1.13, Molecular analysis of the Dj Geor~e critical re~ion (DGCR) 
Only large interstitial deletions of chromosome 22 can be observed cytogenetically 
with high resolution karyotypes (Greenberg et al., !988a), and so deletions of less 
than 3-5 x 106 base pairs are not reliably detectable using cytogenetic analysis. It is 
therefore necessary to employ techniques such as in situ hybridisation (ISH) to detect 
microdeletion 22q II. In one study a series of ten patients affected by DOS were 
screened by high resolution banding and FISH of a cosmid probe. All ten patients 
had a microdeletion of22qll by in situ hybridisation. However, only two of the ten 
were suspected of having this deletion by high resolution banding (Desmaze eta!., 
!993a). 
1.14. In situ hybddisation (ISH) 
In situ hybridisation is based on the double-stranded nature of DNA. When 
denatured the two strands of DNA separate and then quickly rejoin (Leversha, 1993). 
The principle by which ISH works is to incorporate a DNA probe during the 
renaturation process into the chromosomal DNA of an intact chromosome. A DNA 
hybrid is then formed between a single strand of the probe DNA and its 
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complementary single strand of chromosomal DNA as they reanneal, The probe is 
labelled so that when it is joined to the chromosomal DNA and forms a hybrid, a 
signal of this region can be detected. 
' 
' 
Initially, probes were labelled isotopically and detected by autoradiography, The ' 
first isotopic in situ hybridisation was based on the early work of Gall and Pardue in 
1969, however this techoique is techoically difficult and potentially hazardous due to 
radioactivity. It is also much slower than non-isotopic in situ hybridisation (NISH), 
' ! as signals can take 2-3 weeks to be detected. Isotopic in situ hybridisation has 
largely been superseded by NlSH (Lichter & Ward, 1990), In NISH, hybridisation 
usually takes place overnight and the probe is detected by a reporter molecule bound 
to a histochemical stain aggregate sufficiently large to permit visualisation. 
f 
' Enzymes such as horse radish peroxidase will catalyse the precipitation of deposits 
,, : 
which can be seen with a light microscope (Leversha, 1993), Alternatively, 
fluorochromes can be linked to the probe via a reporter molecule that, after 
hybridisation, binds to fluorescent affinity reage.,ts. Probes may also be directly 
conjugated with fluorescent molecules, the most common of which are fluorescein 
isothiocyanate, rhodamine and Texas Red (Trask, 1991), Fluorescent labels have the 
added advantage that chromosomes can be simultaneously Q-banded as well as have 
probes hybridised to them. 
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1.15. FISH and the detection ofDGS 
FISH has been successfully used to detect DGS by several research groups. Carey et 
a/. (1992) were able to demonstrate that 21 out of22 patients suspected of having 
DGS were hemizygous for 22q II. When this result was combined with one of their 
earlier studies, 33 out of 35 DGS patients had chromosome 22qll deletions 
detectable by DNA probes (Carey eta/., 1992). A similar study also using a cosmid 
probe showed 10 out of 10 patients to have a detectable 22qll deletion, whereas 
only two of the ten were diagnosed cytogenetically (Desmaze et a/., 1993a). A 
second study by the same researchers describes the relative ordering by FISH of 
cosmid loci and translocation breakpoints in the Di George syndrome critical region 
(DGCR) of chromosome 22 (Desmaze eta/., 1993b). Such studies aim to define the 
smallest region which can be lost and still result in DGS. As well as providing a 
diagnostic tool for DGS patients, FISH can also be utilised for prenatal diagnosis and 
genetic counselling (Driscoll eta/., 1993). The use of a cosmid probe in FISH has 
also enabled researchers to show that similar conditions may in fact be related to 
.,, 
DGS. Burn et a/., (1993) showed that a cosmid probe could delineate a 22qll 
deletion in the conotruncal anomaly facial syndrome. 
1.16. In silu hybridisatjoo as a research tool 
ISH can be used to fmd the chromosomal location of DNA probes. A probe for the A. 
immunoglobulin light chain cluster (A. IGLC) constant region was hybridised to 
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chromosome preparations of two patients with DGS-related translocations. The 
results showed that the gene in question, A. IGLC, was not involved in DGS 
',i 
(Cannizzaro and Emanuel, 1985). Although this study did not show the location of 
the DGS gene or genes to be within the A.IGLC region, it effectively eliminated this 
area from the search for such a region in 22q 11. There have been many similar 
studies undertaken with respect to the physical mapping of the DGCR, which was 
narrowed down to chromosome 22qll.21-tq11.23 by Fibison et a/. (1990). 
Numerous DNA makers which are deleted in patients with DGS have been mapped 
to the 22qll-pter region (Carey eta/., 1990), and these markers provide a basis for 
adding fine detail to the proximal map of 22q II. 
Other anonymous DNA markers for the DGCR have since been mapped using 
hybrids from patients with DGS (Sharkey et a/., 1992). One such study (Budarf et 
a/., 1992) indicated that a gene may have been isolated from the DGCR, although the 
complete sequeflce, function and development expression pattern of the gene have 
not yet been determined. One of the most recent cosmid markers, cHKAD-26 
(Kurahashi eta/., 1994) to be assigned to the DGCR was from a genomic cosmid 
library constructed from a Chinese hamster/human hybrid, this marker may prove 
useful in the clinical diagnosis of DGS and VCFS. Another 108 cosmid markers 
were regionally assigned to human chromosome 22 in the search for the DGCR 
probe. It is envisaged that these will be used for further investigation in the 
_,._·__ - '_,,_, 
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construction of long range physical maps and for localising genetic alterations on the 
chromosome (Kurahashi eta/., 1994). 
1.17. The clinjcal use of jn situ bybridjsation 
In situ hybridisation can be used as a clinical diagnostic tool not only for DGS and 
VCFS but also for many chromosomal abnormalities. As well as the ISH of 
metaphase chromosomes, interphase nuclei analysis has also been suggested. This 
method is a rapid and efficient tool in the identification of trisomy 21 (Lichter et al., 
1988). 'Chromosome painting' has been recommended as a diagnostic adjunct to 
classical metaphase analysis (Hulten et a/., 1991). FISH is now used in many 
cytogenetic laboratories as a diagnostic tool and probes for a large number of 
chromosomal abnonnalities are commercially available. 
One of the most recent molecular n.~thods in the detection of specific chromosome 
regions is the 'PRINS' technique. It enables rapid chromosome identification by 
oligonucleotide-primed in situ DNA synthesis. Labelled nucleotides are 
incorporated directly into the DNA of cytological preparations. The primary 
advantage of PRINS over ISH is that detection takes just two hours, as compared to 
an overnight reaction. For this reason the PRINS technique may well become the 
preferred method in the future (Gosden and Lawson, 1994). 
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II. Materials 
II. 1. List of chemicals used 
Chemical Supplier 
Acetic Acid (96%) Merck 
Acetic Acid Glacial Rhone Poulenc 
Laboratory Products 
Agarose (DNA grade) Progen Industries Ltd 
Aluminium Sulphate Sigma 
Anti-digoxigenin-fluorescein, Fab fragments Boehringer Mannheim 
Anti-digoxigenin-POD, Fab fragmonts Boehringer Mannhehu 
Anti-fluorescein-POD, Fab fragmen!J Boehringer Mannheim 
Bam HI Prom ega 
Bacto-tryptone Difco Laboratories 
Bacto-yeast extract Difco Laboratories 
Biotin-16- dUTP Boehringer Mannheim 
Benzyl Penicillin (600mg/vial) CSL (Commonwealth 
Serum Laboratories) 
Bovine Serum Albumin (lyophilized powder) Sigma 
Bromophenol blue 
Caesium Chloride (dihydrate) 
Chlorofonn 
Colcemid (Gibco BRL) 
CuS04 
DABco• 
2' -Deoxycytidine 
DePeXmounting medium 'Gurr'® 
Dextran Sulphate 
3,3 '-Diaminobenzidine (powder) 
3,3' -Diaminobenzidine Sigma fastTM(tablets) 
DIG DNA labelling and detection Kit-
( digoxigenin-11-dUTP) 
Dimethyl fonnamide 
DNA (from herring spenn) 
EcoRI 
Ethanol 
Ethidium Bromide 
Ethylenediaminetetraacetic acid Disodium Salt (EDTA] 
Etylene glycol (ethanediol) 
Fetal bovine serum (Gibco BRL) 
Fluorogreen (fluorescein-11-dUTP) 
Sigma 
Sigma 
AualaR0 BDH 
Life Technologies 
Sigma 
Aldrich 
Sigma 
AualaR0 BDH 
Phannacia 
Sigma 
Sigma 
Boehringer Mannheim 
AualaR0 BDH 
Boehringer Mannheim 
Promega 
.AualaR® BDH 
Sigma 
Sigma 
Sigma 
Life Technologies 
Amersham 
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Fonnamide (redistilled) 
Giemsa' s Azur~eosin~methylene blue 
Glucose 
Haematoxylin 
HCl 
Heparin (I OOOunits/ml) 
Hind III 
Human COT-I™ DNA (Gibco BRL) 
HybondN+ 
Hydrogen Peroxide solution (-30%) 
8-Hydroxyquinoline 
iso-amyl alcohol (Univar) 
Kanamycin monosulphate 
K2HP04 
L-glutamine (Gibco BRL) 
Lithium Chloride 
Lysozyme 
2-mercaptoethanol (also ~-mercaptoethanol) 
Methanol 
Mixed bed ion exchange resin 
NaCl 
Progen Industries Ltd 
Merck 
AnalaR®BDH 
Sigma 
AnalaR®BDH 
CSL (Commonwealth 
Serum Laboratories) 
Promega 
Life Technologies 
Amersham 
AnalaR®BDH 
AnalaR®BDH 
Ajax Chemicals 
Sigma 
AnalaR®BDH 
Life Technologies 
Sigma 
Sigma 
Bio-Rad 
AnalaR®BDH 
Bio-Rad 
AnalaR®BDH 
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Na2HP04 AnalaR"BDH 
NaOH AnalaR"BDH 
Nick Translation kit™ Boehringer Mannheim 
N-laurylsarcosine blocking reagent Boehringer Mannbeim 
OptiMEM" I (reduced serum medium) Life Technologies 
Phenol Progen Industries Ltd 
Phytohaemagglutinin P Difco Laboratories 
Polaroid T667 film Kodak® 
Potassium Acetate AnalaR® BDH 
Propan-2-ol (Isopropanol) AnalaR" BDH 
Propidium Iodide (95-98%) Sigma 
Proteinase K Promega 
Restriction enzyme lOx buffer (B, C & H) Promega 
RN ase A Sigma 
Streptavidin-fluorescein Boehringer Mannheim 
Streptomycin Sulphate Sigma 
Sodium Citrate AnalaR" BDH 
Sodium Dodecyl Sulphate [SDS] Bio-Rad 
Sodium Iodate Sigma 
Thymidine Sigma 
TRIZMA" base Sigma 
TWEEN"20 [Poly( oxyethylene ),-sorbitan monolaurate] Boerhringer Mannbeim 
Westart cement 
Whatman'" Filter paper #I 
Xylene Cyanole F'P (Acid blue) 
29 
Jacksons, Subiaco, W A 
Selby 
Sigma 
11.2. Rea~ents in use 
Anti-fade mountin(i! media 
Tris·CJ 20 mM pH 7.5 I part 
Glycerol (containing DABCO 2%) 9 parts 
To make glyceroVDABCO: 
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Dissolve 360mg ofDABCO into 18m! of glycerol at 70°C for 5 minutes. 
To make antifade: 
Add 2m! of Tris'Cl 20 mM (pH 7.5) to 18m! of glycerol/DABCO mixture. 
Mix on wheel for 2 hours, then store at 4 °C. 
(Laboratory Manual, Dept. of Cytogenetics and Molecular 
Genetics, Adelaide Children's Hospital, SA. -FISH technique) 
Buffer# 1 (For Minipreparations of DNA) 
50mM glucose 
25mM Tris-Cl (pH 8.0) 
lOmM EDTA (pH 8.0) 
The above solution is prepared in batches of 500ml, it is then autoclaved for 15 
minutes at JO!b/sq.in. on liquid cycle, and stored at 4°C. 
(Sarnbrook eta/., 1989, p. B.22) 
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Buffer# 2 (For Minipreparations of DNA) 
0.2M NaOH (freshly diluted from 10M stock) 
1%SDS 
Buffer stored at room temperature 
Buffer# 3 (For Minipreparations of DNA) 
5 M potassium acetate 
glacial acetic acid 
H20 (double distilled) 
60ml 
11.5ml 
28.5 ml 
(Sambrook eta/., 1989, p. B.22) 
The resulting solution is 3 M with respect to potassium and 5 M with respect to 
acetate. 
Dejonised Fonnamjde 
Fom1amide (redistilled) 
Mixed-bed ion exchange resin 
(Sambrook eta/., 1989, p. B.22) 
500ml 
25g 
Place formamide and resin in a dark bottle on a magnetic stirrer for at least one hour. 
After this time filter formarnide twice through Whatman filter paper #I and store in 
aliquots of 50ml at -20°C until needed. [NB. formamide is deionised when there is 
no yellow colour in it and some of the resin remains blue.] 
(Sambrook eta/., 1989, p.l.l 02) 
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0.5 MEDIA (pH 8.0) 
Disodium ethylenediaminetetraacetic acid (EDTA) 
H20 (double distilled) 
186.lg 
800ml 
Add water to EDTA and stir vigorously on a magnetic stirrer. Adjust the pH to 8.0 
with NaOH (EDTA will not go into solution until pH is adjusted). Dispense solution 
into lOOm! aliquots and sterilise by autoclaving (15 minutes at IOlb/sq.in. on liquid 
cycle). 
(Sambrook el a/., 1989, p.B. II) 
Ethidjum Bromide 
Ethidium Bromide 5.0g 
Double distilled water500ml 
Add ethidium bromide to water and stir on magnetic stirrer for several hours un~il the 
dye had dissolved. Store at room temperature in a dark bottle. NB: Gloves and 
mask should be worn when handling ethidium bromide. 
Gill's Haematoxylin (1.5 x strenf>lh), 
To make 1.5L: 
Ethylene glycol (ethanediol) 375m! 
Haematoxylin 4.5g 
Sodium Iodate 0.45g 
(Sambrook eta/., 1989, p. B. II). 
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Aluminium Sulphate 39.6g 
Glacial Acetic Acid 30m! 
Double-distilled water 1080ml 
All of the reagents are mixed for at least 1 hour before the glacial acetic acid is l-
added. This solution is stored at room temperature. 
(Laboratory maoual of Histopathology Department at the University of Western 
Australia, Department ofpathology). 
Hybridisation buffer (to check the labelling of probe). 
Dilution ofthe following reagents is made into SxSSC 
N-laurylsarcosine Blocking reagent 5%w/v 
(Boehringer Maonbeim) 
Sodium salt 0.1% w/v 
SDS 0.2%w/v 
This solution is cloudy when made and it is stored at 4°C. 
(Karen Smith, University Department ofpathology UW A. Personal correspondence). 
"Kevit's" Hybridjsation Mix. 
To make lOOm!: 
Dextrao sulphate (10%) lOg 
20xSSC !Oml 
Formamide-deionised (FA) 50ml 
TWEEN"20 (0.1 %) 
Double distilled water (ddH20) 
O.lml 
39.9ml 
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Mix FA, SSC, and ddH20, pH to 7.0. Add dextran sulphate and stir at room 
temperatore for 1-2 hours. Remove from stirrer and add TWEEN®20, roll to mix. 
Aliquot useful lots into Eppendorf tubes (eg. 100~1) and store at -20°C. Discard 
unused portion once thawed. 
J;B Agarose 
(Laboratory Manual, Dept. of Cytogenetics and Molecular 
Genetics, Adelaide Children's Hospital, SA. -FISH technique) 
First prepare LB liquid media and then add agarose. 
LB liQllid Medium (Luria-Ber/ani Medium): 
Per litre: 
To 950ml of double distilled water (ddH20), add: 
Bacto-tryptone 10 g 
Bacto-yeast extract 5g 
NaCl lOg 
Shake until the solutes have dissolved. Adjust the pH to 7.0 with 5 N NaOH 
(- 0.2ml). Make up to a final volume of !litre with dd H20. Sterilize by autoclaving 
for 20 minutes at 15lb/sq.in. on liquid cycle. 
To prepare LB agarose make LB medium from the recipe above. Just prior to 
autoclaving add one of the following: 
., 
' 
-·: 
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!5g/L ofagarose for plates or 7g/L for top agar. 
To sterilize autoclave as above. Before pouring plates allow agarose to cool to -
50°C add any heat labile substances at this temperature (eg. antibiotics). 
(Sambrook eta/., 1989, p. A.! & A.4) 
Lithium Chloride (LiCI) for random primed labelling reaction 
4M LiCI solution is used in the random primed method, however 
3M sodium acetate or 
3M sodium chloride may be substituted for LiCI. 
(Boehringer Mannheim, The DIG system user's guide for filter hybridisation, p. 7) 
Loadina buffer (for electrophoresis gels) 
6x Buffer type Ill 0.25% bromophenol blue 
0.25% xylene cyanole FF 
30% glycerol in water 
This buffer is stored at 4°C. 
(Sarnbrook eta/., 1989, p.6.12) 
Opti-MEM (Blood culture medium) 
To lOOm! of OptiMEM® 1 add by sterile technique:-
L-glutamine !.Om! 
Penicillin and Streptomycin !.Om! 
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Heparin (1 OOOU/ml) !.Om! 
Phytohaemagglutinin !.25m! 
Fetal Bovine serum 5.0ml 
Store medium at 4°C, after the above reagents are added to OptiMEM discard 
unused portion within 2 weeks. 
(Cytogenetics Laboratory manual, p.64. SHLS, WA). 
-! 
Phosphate Buffered Saline (l'BS) 
NaCl 8.0g 
KCl 0.2g 
Na2HP04 1.44g 
0.24g 
Dissolve the above in 800ml of double distilled water (ddH,O). Adjust the pH to 7.4 
with HCl and add ddH20 to make a final volume of 1 litre. Sterilise by autoclaving 
for 20 minutes at lSib/sq.in. on liquid cycle, then store at room temperature. 
(Sarnbrook eta/., 1989, p. B.l2). 
Phenol (equilibrated) 
Before use phenol must be equilibrated to a pH >7.8. 
Phenol prior to equilibration should be stored at -2G°C. To equilibrate: 
I. Remove phenol from freezer, allow it to warm to room temperature and 
melt it at 68°C, 
j 
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-; 2. Add hydroxyquinoline at a final concentration of 0.1 %, this gives the 
phenol a yellow tinge and allows rapid identification of the organic phase. 
3. To the melted phenol add an equal volume of buffer [O.SM Tris'Cl pH 8.0 
at room temperature]. Stir the mixture on a magnetic stirrer for 15 minutes. 
AHow the two phases to separate and aspirate as much as possible of the 
upper aqueous phase. 
I 
4. Repeat step 3. as many times as is required to get phenol to a pH of >7.8 
- .; (measure pH with pH paper). 
_,, 
5. After phenol is equilibrated and final aqueous layer is removed, add 0.1 
volume of O.IM TrisCl (pH 8.0) containing 0.2% P-mercaptoethanol. 
Phenol solution is stored in this form under 1 OOmM TrisC1 (pH 8.0) in a dark 
bottle at 4•c for up to 1 month. 
(Sambrook el a/., 1989, p. B.4). 
Phenol:Chlorofonn:lsoamyl alcohol(25 :24:1) 
Phenol is equilibrated as above and added in equal parts to cbloroform:isoarny1 
alcohol (24:1). Neither chloroform nor isoamyl alcohol require treatment before use. 
The pheool:chloroform:isoarnyl alcohol mixture is stored under 1 OOmM Tris'CI (pH 
8.0) in a dark bottle at 4•c for up to 1 month. 
(Sarnbrook el a/., 1989, p. B.S). 
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RNaseA 
Sodium acetate O.OlM (pH 5.2) 
Tris·CllM 
Dissolve RNase A to a concentration of !Omg!ml in sodium acetate. Heat to 100°C 
for 15 minutes, allow to cool and adjust the pH by adding 0.1 volumes of lm Tris'Cl 
(pH 7.4). Dispense into 500J.1l aliquots and store at -20"C. For RNase slide 
preparation prior to in situ hybridisation dilute RNase A to a concentration of 
1 OOJ.!g/ml with sterile water or 2xSSC. 
Scott's tap water substitute. 
To make 2litres: 
Sodium bicarbonate 
Magnesium Sulphate 
Crystal thymol 
Tap water 
7.0g 
40g 
(Sambrook eta/., 1989, p. B.l7). 
3-6 crystals 
approximately 2 litres 
All reagents are mixed in 1.8 litres oftap water until completely dissolved, then the 
final volume of the solution is made up to 21itres. 
(Laboratory manual of Histopathology Department at the University of Western 
Australia, Department of Pathology). 
Sodium dodecyl sulphate (SDS) 
SDS (electrophoresis grade) 
Double distilled water ( ddH20) 
IOOg 
I litre 
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Dissolve SDS in 900ml of ddH20. Heat to 68'C to assist dissolution and adjust pH 
to 7.2 by adding a few drops of c.HCI, make up to a final volume of I litre and store 
at room temperature. 
STE buffer 
NaCI (0.1 M) 
Tris"CI (!OM, pH 8.0) 
EDTA (lmM, pH 8.0) 
(Sambrook eta/, 1989, p. B. 13). 
Mix NaCI, Tris'CI, and EDTA solutions of the above concentrations to final pH of 
8.0. Sterilise by autoclaving for 20 minutes at !Sib/sq.in. on liquid cycle. Store at 
room temperature. 
20XSSC 
NaCI 
Sodium Citrate 
Double distilled water (ddH20) 
175.3g 
88.2g 
"'I litre 
(Sambrook eta/., 1989, p. B.I3). 
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Dissolve NaCI and sodium citrate in 800ml of ddH20 and adjust pH to 7.0 with I OM 
NaOH, make up to a final volume of I litre with water. Sterilise by autoclaving for 
20 minutes at lSlb/sq.in. on liquid cycle. Store at room temperature. 
TAEbutfe1 
SOx stock solution Tris base 
glacial acetic acid 
0.5M EDTA (pH 8.0) 
(Sambrookelai., 1989,p. B.13). 
242g 
57.lml 
lOOm! 
lx buffer contains 0.04M tris acetate and O.OO!M EDTA 
(Sam brook eta/., !989, p. B.23) 
Tris- buffered saline (TBS) 
NaCI 8.0g 
KCI 0.2g 
Tris base 3.0g 
Dissolve the above into 800ml of double distilled water (ddH20), and adjust pH to 
7.4 with HCI. When desired pH is achieved make up to a final volume of I litre with 
ddH20. Sterilise by autoclaving for 20 minutes at 15lb/sq.in. on liquid cycle. Store 
at room temperature. 
(Sambrook eta/., 1989, p. B.l4). 
IE Buffer (pH 7.4) 
I OmM Tris·ct pH 7.4 
lmM EDTA pH 8.0 
This buffer is stored at room temperature. 
Iris-HCl buffer 
Tris base 
Double distilled water (ddH20) 
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(Sambrook eta/., 1989, p. B.20). 
121.1g 
"'lL (less due to addition ofHCl) 
Add Tris base to 800ml of water and adjust pH by adding concentrated HCl:-
eg. pH c.HCI 
7.4 70ml 
7.6 60ml 
8.0 42ml 
Make final adjustments to pH when solution is at room temperature, make up to final 
volume of 1 litre. Sterilise by autoclaving for 20 minutes at 15lb/sq.in. on liquid 
cycle. Store at room temperature. [NB the pH of Tris solutions is temperature-
dependent and decreases approximately 0.03 pH units for each 1 °C increase in 
temperature]. 
(Sambrook eta/., 1989, p. B.l4). 
2xYTmedh:m 
Per Litre: 
To 900ml of double distilled (ddH,O), add·. 
Bacto-tryptone 16g 
Bacto-yeast extract lOg 
NaCl Sg 
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Shake until the solutes have dissolved. Adjust the pH to 7.0 with 5 N NaOH. Make 
up to a fmal volume of llitre with dd H00. Sterilize by autoclaving for 20 minutes at 
15lb/sq.in. on liquid cycle. 
2~YT Agarose 
To prepare 2x YT agarose make 2x YT medium from the recipe above. Just prior to 
autoclaving add one of the following: 
15g/L ofagarose for plates or 7g!L for top agar. 
To sterilize autoclave as above. Before pouring plates a11ow agarose to cool to -
50°C add any heat labile substances at this temperature (eg. antibiotics). 
(Sarnbrook eta/., 1989, p. A.3 & A.4) 
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III. Methods 
III. 1 . Preparation of a cosmjd for labellin~ 
III. I .i). Chromosome 22 specific cosmid probes 
Two different cosmid probes were used for in situ hybridisation. The first, cosmid 
Cl79, was obtained from Prof. J Burn of the Department of Human Genetics at the 
University of Newcastle upon Tyne, U.K. It is a unique copy probe for a single 
repeat region of the genome which corresponds to chromosome 22q 11. This region 
is believed to be deleted in affected individuals with DGS. The other cosmid probe 
used was D22S75, and it too is a marker within the DGCR. The probe was 
purchased from ONCOR®, Gaithersburg, USA. The commercial probe is prepared 
for in situ hybridisation prior to purchase. It is labelled with digoxigenin and 
packaged in a hybridisation solution as single stranded DNA. This means that it 
requires no labelling or denaturation before hybridisation, unlike the donated probe. 
Ill. l.ii). The preparation of non-commercial cosmid probes 
Cosmid C179 arrived from the U.K. in a kanamycin-resistant strain of enterobacteria, 
as a stab culture. (Despite repeated queries to the donor laboratory for further 
details, infonnation on the provenance of the probe and the host organism were not 
forthcoming). To isolate the cosmid probe from the stab for use in an in situ 
hybridisation experiment, the bacteria was streaked on to an agar plate, containing 
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kanamycin, and allowed to grow. A single colony was then amplified in the 
appropriate medium. Once amplified, the cosmid was extracted from the bacteria by 
alkaline lysis and purified. Cosmid Cl79 was isolated and purified using this 
method by Dr. E. Edkins at the Molecular Biology Department of Princess Margaret 
Hospital for Children('/{ A). After the probe DNA was extracted and purified, it was 
ready for in situ hybridisation with metaphase chromosome spreads. A small-scale 
preparation (termed a mini-preparation, Sarnbrook et a/., 1989 p.l.25) was first 
attempted, to ensure presence of the desired cosmid in the bacteria. When this had 
been confirmed, a large scale version was performed. 
III.l .jii). Isolation of cosmjd DNA from bacteria (Smale-scale preparation of C179) 
DAY!: 
A loop of cosmid C 179 was first streaked on to a 2x YT agarose plate by sterile 
technique. The agarose contained kanamycin at a concentration of !Of!g/ml. To 
pour the plate, 2xYT agarose (see 'II.2. Reagents in use') was autoclaved and 
allowed to cool in an incubator to around 50°C. This temperature is sufficiently cool 
to permit the addition of antibiotic to the agar without altering the molecular 
structure of the antibiotic and destroying its effect. After the agarose had been mixed 
with the kanamycin, the plates are poured and left to set. A loop of the kanamycin-
resistant bacteria which contains C 179 could then be removed from the stab culture 
and streaked onto a 2xYT agarose plate. The plate was then inverted and incubated 
at 37'C overnight. 
Ill. l.iv). Amplification of cos mid DNA 
DAY2: 
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To culture the bacteria containing Cl79, a single colony of Cl79 was transferred 
from the agarose plate into 2m! of2xYT medium containing kanamycin (I 0J.lg/ml) in 
a loosely capped 15m! tube. The tube was again incubated at 37'C overnight with 
vigorous shaking. 
DAY3: 
An aliquant of culture (l.Sml) was pipetted into a microcentrifuge tube with any 
surplus culture stored at 4 'C. The tube was centrifuged at 12 OOOg for 30 seconds at 
4 °C in a microfuge. The supernatant was removed from the tube by aspiration and 
inverted on to a paper towel for 2 minutes, this ensured that the bacterial pellet was 
as dry as possible. The pellet was resuspended by vigorous vortexing in 1 00}ll of ice 
cold Buffer #I (see '1!.2. Reagents in use' for Buffers #1, #2 & #3). Freshly 
prepared Buffer #2 (200J.ll) was added, the cap on tube replaced tightly, and the 
contents mixed by rapidly inverting the tube 4-5 times. The tube was then placed on 
ice and !SOJ.!I of ice cold Buffer #3 added. The tube was vortexed gently for 10 
seconds to disperse Buffer #3 through the viscous lysate, and placed back on ice for 
3-5 minutes. After this intervai the tube was centrifuged at 12 OOOg for 5 minutes at 
4 °C in a microfuge and the supernatant transferred to a fresh tube. 
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III.l.Y). Precipitation ofcosmjd DNA 
The DNA was precipitated with 2 volumes of ethanol at room temperature and the 
tube mixed by vortexing. The mixture was allowed to stand at room temperature for 
2 minutes, and the tube then centrifuged at 12 OOOg for 5 minutes at 4°C in a 
microfuge. The supernatant was removed by gentle aspiration and the tube allowed 
to stand in an inverted position on a paper towel to allow all of the fluid to drain 
away. The DNA pellet was rinsed with lml of 70% ethanol at 4'C and the 
supernatant removed as before without disturbing the pellet. The pellet was allowed 
to dry at room temperature for 10 minutes and then redissolved in SOJ.!l of TE buffer 
(pH 8.0) containing 20JJgiml of DNAase free RNase A. After vortexing briefly the 
DNA was stored at -20'C. 
III.l.yi). Determination of the concentration and purity of cosmjd DNA by the 
absorbance method 
To measure the abso.oance of the DNA sample at a wavelength of 260nm and 
280nm, a I :2 000 dilution of the DNA sample was made in sterile water. The 
spectrophotometer was blanked with sterile water at both wavelengths and the 
absorbence of the sample measured. The concentration of the DNA in the sample 
could then be calculated with the use of a software packaged linked to the 
spectrophotometer. 
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III. I .vii). Verification of presence of cosmid DNA 
A sample ofcosmid C179 DNA which bad been extracted from the bacteria by mini-
preparation, was run on an agarose mini~gel to verify the presence of insert DNA and 
to determine if any contamination was present. An agarose gel (0.8% in T AE buffer) 
was poured on to a mini-gel tray, a small toothed comb inserted and the gel allowed 
to set for 10 minutes. When set the comb was removed and the DNA sample to be 
tested was loaded into the one of the wells along with markers of known size in the 
adjacent wells. The gel was run at a constant 100 Volts for I hour. It was then 
removed from the gel tray and washed in ethidium bromide with agitation for I 0 
minutes. "The gel was then visualised on a fluorescent (UV) light box, photographed 
and the photograph then analysed, the distance that the DNA travelled through the 
gel is indicative of its fragment size when compared to the size of the known marker 
(in this case'/.. Pst 1). The un-cut probe DNA purity could be estimated by comparing 
the number of bands which appear in the probe DNA lane to those of a known pure 
control sample photograph. This comparison was usually made between the 
photographs of the control and the tested DNA. 
III.l.yiji). Larfi:e scale preparation ofcosmjd DNA 
When the cosmid DNA had been isolated by mini-preparation, a large scale or what 
is termed a maxi-preparation was set up. This preparation is a modified version of 
the alkaline lysis mini-preparation method (Felliciello and Chinali, 1993), and it 
yields a greater volume of probe DNA. The protocol for this procedure was; 
49 
DAY!: 
A single colony of kanamycin-resistant bacteria containing Cl79, was transferred 
into 500ml of 2x YT media (I O~g/ml kanamycin) in a 2 litre capacity conical flask. 
The flask was incubated overnight at 3 7°C with vigorous shaking. 
DAY2: 
The contents of the flask were transferred into 2 centrifuge bottles (250m!) and spun 
at 4000g in a Sorvall GS3 rotor for 15 minutes at 4 •c. The supernatant was 
discarded and the bottles allowed to drain in an inverted position on paper towels. 
The bacterial pellets in each bottle were then resuspended in 50ml of ice-cold STE 
buffer. After mixing the bottles were centrifuged at 4000g in a Sorvall GS3 rotor for 
15 minutes at 4"C. The supernatant was discarded and 9ml of ice-cold buffer #I 
added, the bottles were then stood at room temperature for 5 minutes before 20m! of 
fl·eshly prepared buffer #2 was added. The caps on the bottles were replaced tightly, 
and they were then inverted several times. Ice-cold buffer #3 (!Om!) was added to 
the bottles, they were shaken vigorously, and stood on ice for 10 minutes. The 
resulting lysate was centrifuged at 4000g for 15 minutes at 4"C. After this interval 
the supernatant from both bottles was filtered through 4 layers of cheesecloth into a 
single Oak Ridge tube and centrifuged at 5000g for 15 minutes at room temperature. 
The supernatant was carefully decanted from the tube and the pellet and the walls of 
the tube were rinsed in 70% ethanol at room temperature. All ethanol was drained 
from the tube by inversion for several minutes on to a paper towel, after which time 
the pellet was Jisoolved in 3m! ofTE buffer (pH 8.0). 
-~ 
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The Cl79 cosmid DNA was then purified by equilibrinm centrifugation in CsCI-
ethidium bromide gradients. After isolation, the purity and concentration of the 
probe were tested by the same methods as described in the small-scale preparation of 
probe DNA. 
Ill.2. Labellin~ ofcosmjd DNA 
Jll.2.i). Methods oflabellin~ cosmjd DNA 
There are three different methods of labelling cosmid DNA for use with in situ 
hybridisation. These are the direct, nick translation, and random priming methods. 
Each is outlined below:-
11!.2.j),a. Fluorescein direct-labelling method 
This method labelled the DNA directly, i.e., biotin or digoxigenin were not required. 
The fluorescein was incorporated into the cosmid DNA, rather than attached to a 
hapten or reporter molecule. The DNA was diluted in sterile water to the desired 
concentration. Then, using a nick translation kit, the fluorescein was incorporated 
into the cosmid DNA. The tubes from the nick translation kit were thawed and then 
placed on ice. It should be noted that Klenow enzyme must be kept at -20'C, to 
protect its activity. Once the rest of the kit had thawed, nucleotides and water were 
added to the DNA according to the following protocol: 
Cosmid C 179 (l j.!l) at a concentration of I 00 ng/fil was placed into a clean 
microcentrifuge tube, to which the following were added: 
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IOfil dATP, lOfil dCTP, lOfil dGTP, 2fil dTTP, lfil ofFluorogreen (always kept 
in dark) (Amersharn), llfil of sterile water (to make up to a final volume of 50f!l) 
aod 5fil of enzyme directly from the freeze;, The tube was then centrifuged in a 
microfuge at 12 OOOg for 20 seconds. The tube was incubated for 4 hours at l5°C 
aod the reaction stopped by the addition of 5fil of 0.2 M EDTA. The labelled probe 
was then pipetted into IOfil aliquots and stored in the dark at -20°C. 
111,2.i).b. Nick translation 
An aliquot of extracted C 179 was sent to the Department of Cytogenetics and 
Molecular Genetics at the Adelaide Women's aod Children's Hospital. This sample 
was labelled by nick-translation using the method developed by David Ward and co-
workers at Yale University (Langer et a/., 1981), as described below: 
Labemmi reaction for nick~translation:-
The following reagents were mixed in an Eppendorf tube, 5J.ll of I Ox concentration 
nick-translation buffer (0.5M Tris-HCl; pH 7.8, 50mM MgCl2, 0.5mg/ml BSA, 
nuclease free), 5f!l of IOOmM Dithiothreitol (DTT), 4fil of deoxynucleotide 
triphosphates (0.5mM dATP, dGTP, dCTP, each), lfil of 0.5mM dTTP, 2f!l of !mM 
Biotin-16-dUTP (Fluorescein or digoxigenin could alternatively be used), lfig of 
Cl79 probe, lfil ofDNAase I (l 000 times diluted from lmg/ml stock) and 10 urtits 
(l fll) of DNA polymerase I. The mixture was made up to a final volume of 50 fil 
with sterile water and after mixing was incubated for 2 hours at l5°C. The reaction 
was stopped by the addition of 5fil 0.5M EDTA (pH 7.4). The DNA was then 
purified by Sephadex G-50 chromatography using a pasteur pipette column, 
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equilibrated with !OmM Tris-HC!, ImM EDTA and previously flushed with 0.1% 
SDS (to prevent non-specific binding). The high molecular weight DNA eluted in 
the second 600 ftl; this fraction was collected and stored at -20'C. 
lll.2,i),c. Rand9m priming metbod oflabellin~ DNA 
This third method· was carried out on a portion of the extracted cosmid probe. In 
each reaction between 3ftg to lOng of DNA could be labelled. The DNA 
concentration of C I 79 was 0.1 ftg/fll and I O~tl was used i.e., in this instance I flg of 
DNA was labelled. The DNA was first denatured in an Eppendorf tube with a hole 
pricked in its lid, by heating it in a boiling water bath (I OO'C) for I 0 minutes. It was 
removed from the water bath and immediately placed on ice for 5 minutes. 
The following reagents were then added to the tube on ice; 2~tl of hexanucleotide 
mixture, 2~tl of dNTP mixture, 5~tl of nuclease-free water (to make up to a volume of 
19~tl) and l~tl of Klenow enzyme, which resulted in a total tube volume of 20ft!. It 
was ensured that the cap was firmly fastened on to the tube, the tube was briefly 
vortexed and then centrifuged in a microfuge at 12 OOOg ("' 10-20 seconds). The 
tube was incubated overnight in a waterbath at 37°C. The next day the reaction was 
stopped by the addition of 2~tl of 0.2 M EDTA (pH 8.0). The labelled DNA was 
precipitated with 2~tl of 4M LiCI and 60~tl of pre-chilled absolute ethanol (-20'C). 
The tube was well mixed and left for 1 hour at -70'C, then centrifuged for 5 minutes 
at 12 OOOg (room temperature) and the supernatant removed. The pellet was washed 
with cold (-20'C) 70% ethanol, and dried under a vacuum to zero volume. The DNA 
was dissolved in 50ft! ofTE buffer (pH 8.0) at 37'C and then stored at -20'C. 
" l 
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III.2.ii). The reporter molecules used to label cosmjd probe 
As previously stated {p20), probes need to be labelled either directly or with a 
reporter molecule prior to use for in situ hybridisation reactions. To directly label 
Cl79 Fluorogreen® (fluorescein-12-dUTP) from Arnersham was used, the probe was 
labelled in accordance with the manufacturer's recommendations using a nick-
translation kit. This type of kit was also used to label Cl79 with biotin-16-dUTP. 
Biotin acted as a reporter molecule (or hapten), it was incorporated into the probe 
DNA and detected by affinity cytochemistry. In the case of biotin-labelled probes, 
avidin or streptavidin had a high binding capacity to biotin and were used to detect 
its presence (Langer et a/., 1981 ). The second type of hapten used was digoxigenin-
11-dUTP (DIG), Cl79 was labelled with this molecule by the random prime method. 
Hybridised DIG probes are detected by high affinity anti-digoxigenin antibodies 
which are conjugated to enzymes. 
III.2.iii). Confirmation of probe labellin2 
To confirm that the probe had been labelled, a 5 fll aliquot was hybridised to a piece 
of nylon membrane and detected by the antibody to the label conjugated to an 
enzyme; Cl79labelling with DIG was confirmed by this method: 
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DAY!: 
Unlabelled CI79 (21-'1) was pipetted into an Eppendorftube and 2111 of unlabelled 
salmon sperm DNA into another. The contents of both tubes were denatured by 
boiling in a waterbath at 100°C for 10 minutes, then immediately removed from the 
waterbath and placed on ice. A piece of nylon membrane (Amersham Hybond N\ 
was cut to approximately 2.5 x 5.0 em and a small nick removed from one comer of 
the membrane, below which a cross was drawn with a pencil (see figure IV.l). This 
is to enable the DNA spots which are loaded on to the membrane to be distinguished 
from one another. Two aliquots of Cl 79 were loaded onto the membrane (i!ll each) 
along with two lots of salmon sperm DNA, so that there were 4 separate dots of 
DNA. The position of each dot of DNA relative to one another was recorded. The 
DNA was then bound to the membrane by heating at 62°C for I hour. DIG-labelled 
Cl 79 (51-'1) was pi petted into a microfuge tube, denatured by heating to 100°C in a 
boiHng water bath for 10 minutes, and immediately placed on ice. The membrane 
was put into a hybridisation bag with 1-2 ml of hybridisation buffer (see 11.2. 
Reagents in use), containing 51-'1 of denatured DIG-labelled CI 79. The bag was 
sealed making sure that there were no air bubbles, and the membrane hybridised 
overnight in a water bath set to 68°C. 
DAY2: 
The membrane was removed from the hybridisation bag and washed with agitation 
as follows: 
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2xSSC; 0.1% SDS for 2x5 minutes at room temperature, then O.lxSSC; 0.1% SDS 
for 15 minutes at room temperature. The hybridised DNA on the membrane was 
then detected by the following protocol: 
The membrane was washed briefly (2 minutes) in buffer #!(from Boehringer 
Mannheim label!ing kit; containing IOOmM maleic acid, !50mM NaCI pH 7.5) with 
agitation. It was then incubated in buffer #2 (also from the kit; I% blocking reagent 
in buffer #1) for 30 minutes. The membrane was washed for a second time in buffer 
#I for 2 minutes with agitation. The antibody conjugate (vial 8 from kit; anti-DIG 
alkaline phosphatase) was diluted to a concentration of 1:5000 in buffer #I i.e., 4~1 
of anti-DIG alkaline phosphatase is mixed with 20 ml of buffer #I. The membrane 
was incubated with the diluted antibody conjugate at room temperature for 30 
minutes. It was then washed twice in buffer # 1 at room temperature for 15 minutes 
each with agitation to remove unbound antibody. After washing, the membrane was 
equilibrated for 2 minutes in 20 ml of buffer #3 (from kit; IOOmM Tris-HCI, pH 9.5; 
100 mM NaCI, 50 mM MgCI2). The following solutions were mixed to make the 
colour solution just prior to use; I 0 ml of buffer #3, 45ft] of NBT solution (vial 9 
from kit which contained 75mg/ml nitroblue tetrazolium salt in 70% (v/v) 
dimethylfonnarnide), 35~1 ofX-phosphate solution (vial!O from kit which contains 
50mg/ml 5-bromo-4-chloro-3-indolyl phosphate, toludinium salt in 100% 
dimethylfonnamide). The membrane was incubated with 10 ml of colour solution 
whilst sealed in a darkened box. The colour precipitate which demarcates the 
hybridisation areas on the membrane, usually formed within 10-30 minutes and 
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continued forming for 16 hours. When the required intensity had formed the reaction 
was stopped by washing the membrane in approximately 10 ml of TE buffer at pH 
8.0 (buffer # 4 in kit). A photocopy or photograph of the membrane was taken to 
create a permanent result, the membrane was then dried and sealed in a plastic bag. 
The colour of the precipitate faded upon drying but it could be recovered by wetting 
the membrane in buffer# 4. 
111.3. Pre.paratjon of metaphase chromosome spreads 
Jll.3.i). Collection of peripheral whole blood 
Peripheral whole blood (l-2ml) was taken by veno-puncture from each patient, then 
placed into sterile Sml vials each containing O.lml of heparin (lOOOunits/ml) and the 
specimens sent to the Cytogenetics Department at State Health Laboratory Services. 
Heparin was used because it is an efficient anticoagulant which did not interfere with 
lymphocyte culture. 
IU.3.ii). Culturing of blood. syncbronisatjoo of cell cycle and arrest at metaphase 
Throughout the whole of the culturing process, specimens were handled by sterile 
technique. The tubes were first 'set-up', i.e., 3 sterile tubes (10 ml capacity) of blood 
were set up on each patient, 2 were processed as synchronised cultures and 1 as a 
high resolution c>Jlture. All 3 of the tubes received 0.25 ml of whole blood and 
S.Oml of Opti-MEM supplemented medium, the caps were put on the tubes loosely 
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and they were incubated at 37°C in a C02 enriched environment for 48 hours. After 
which the tubes were removed from the incubator and IOO!Jl of thymidine, was 
added by sterile technique to block DNA synthesis. The tubes were returned to the 
incubator with the same conditions as before for a further 17 hours. After this time 
IOOJ.!l of deoxycytidine was added to release the block on DNA synthesis and the 
cells in culture were allowed to resume the cell cycle in the incubator at 37°C. 
Colcemid (50!Jl) was added after41/ 2 hours to the 2 tubes which were to be used for 
synchronised karyotyping and in situ hybridisation, they were then incubated for a 
further 30 minutes prior to the harvesting the cells. The tube which was to be used 
for high resolution (HRS) karyotyping remained in the incubator for 4 hours and 50 
minutes before it too received SOj.tl of colcemid. It was then returned to the 
incubator for 10 minutes and the cells were harvested at the same time as those of the 
synchronised cultures. 
III.3.iji). Harvesting of lymphocytes and fixation of cell suspension 
The following reagents were needed for harvesting blood cultures:-
KCI (0.057M) warmed to 37'C in a water bath; allow 5ml ofKCI per tube. 
Acetic acid (4%) at room temperature; allow Sml per tube. 
Fixative (3 parts methanol to I part acetic acid) prepared fresh; allow 5ml/wash. 
Procedure: 
Working in a biohazard hood, the blood culture was transferred to a centrifuge tube 
(!Om!) and the cap was screwed on tightly. The tubes were then centrifuged at 1500 
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rpm for 5 minutes, the supernatant was removed and the pellet of lymphocytes 
resuspended. A hypotonic solution was added to the tube (5ml of KCl per tube at 
37"C) and mixed, the tube was then centrifuged at 1500 rpm for 5 minutes to lyse the 
erythrocytes. The tube was carefully removed from the centrifuge, the supernatant 
above the buflY coat removed and the pellet resuspended. Acetic acid (5ml of 4%) 
was added to the tube with mixing and the tubes centrifuged at 1500 rpm for 5 
minutes. All but 0.5ml of supernatant was removed and the pellet was resuspended 
in the excess supernatant. The pellet was washed in Sml of fresh fixative ensuring 
that the tube was well mixed, then centrifuged at 1500 rpm for 5 minutes. The 
supernatant was then carefully removed without disturbing the pellet. A further 5 
minute wash in fixative followed this step and the tube was centrifuged as before. 
The supernatant was removed from the tube (with approximately 0.2ml left in the 
tube) and the pellet resuspended. The cell suspension was then ready to drop as 
metaphase spreads. 
lii.3 .iy). Droppin& and fixation on to mjcroscape sljdes of cell preparation 
With a thin tipped lml disposable pipette, fresh fixative was added to the cell 
suspension drop by drop until the suspension cleared to a very faintly opaque 
consistency. A microscope slide was placed flat on the bench top and, using a fresh 
pipette, from a height of approximately 20cm I drop of cell suspension was dropped 
on to the slide. (All microscope slides were pre-cleaned by soaking in methanol for 
at least 30 minutes and allowed to air dry under a dust cover). Just before the drop 
' ., 
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dried it wa" covered with a drop of fresh fixative and allowed to dry before the slide 
was moved, (as the drop of methanol/acetic acid fix spread across the slide the sides 
were carefully wiped with a tissue to prevent any back-flow of fix interfering with 
chromosome fixation). 
IILJ.v). Examination by phase contrast microscopy 
When the slide was dry it was examined by phase contrast microscopy. Metaphase 
chromosomes should be clearly visible. Chromosomes were judged to be well 
spread when there were at least 20-30 clear metaphases viewed under the 
microscope. Good preparations should be dark grey in colour with a minimal 
amount of cytoplasm visible; if the chromosomes were pale it was a sign that they 
were too dry and ifthey were shiny and black they were said to be refractile. Both of 
these variant fonns would be detrimental for in situ hybridisation or Giemsa banding. 
To prevent chromosomes from being too dry they were dropped onto a microscope 
slide which was placed on top of a paper towel that had been pre-warmed by soaking 
in hot water. Refractile chromosome preparations could be dropped in a fume hood 
next to a lighted Bunsen burner in order to optimise their banding potential. 
III.3.vi). Stora~e of slides and suwius suspension. 
If the slides were not immediately required for dropping, the tubes containing the 
harvested cell suspension were filled to the brim with fresh fixative and stored at 4 'C 
for up to 3 months. Alternatively, only 5ml of fresh fixative was added and they 
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were stored at -20°C for up to I year. After storage the tubes were twice centrifuged 
as before and the supernatant removed, the pellet was then washed both times in 5ml 
of fresh fix before dropping. 
!11.4. In situ hybridisation 
II1.4.i). Protocols for in situ hybridisation 
A number of different protocols were used in order to produce a suitable method for 
in situ hybridisation wHch would be successful with the C179 probe. The protocols 
were modified for the various labelling techniques that were carried out. In the 
following pages these protocols are outlined and the specific variations made to each 
for C179 cosmid probe in situ hybridisation will be expanded upon in the Discussion 
section of the thesis. 
lll.4.i).a. Prow col #I direct method 
The first attempt at in situ hybridisation was using C!79 which had been labelled 
directly with Fluorogreen® (Amersham). It is a modification of the in situ 
hybridisation protocol from the Department of Cytogenetics and Molecular Genetics 
at Adelaide Women's and Children's Hospital and the protocol supplied with the 
fluorochrome by Amersham. 
DAY!: 
!. A Coplin jar (with lid) containing SOml of 70'/o deionised formamide/2xSSC (pH 
7 .0) was left to heat in a water bath set at 70°C. 
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2. RNase A (200~1 of O.lmg/ml) was pipetted on to each slide covered with a glass 
coverslip (22 x 50mm). The slides were incubated for I hour at 3 7°C in a sealed 
plastic container with a 2xSSC saturated environment. 
3. At the end of the hour, the coverslips were removed from the slides and the slides 
washed as follows: 
The slides were washed for 4 x 1 minute in 2xSSC at room temperature with 
agitation, using fresh 2xSSC each wash. The slides were dehydrated through a series 
of alcohols (70% ethanol, 95% ethanol) for 1 minute in each, then rinsed quickly in 
1-2ml of 100% ethanol. The slides were then stood upright and allowed to dry at 
room temperature. When dry they could remain at this stage for several hours. 
4. In order to hybridise probe DNA to chromosomal DNA both were denatured so 
that they were single-stranded. The probe DNA was denatured first, with lOOng of 
probe DNA used per slide. Cl79 with Fluorogreen had a concentration of IOOng/~1, 
therefore 1~1 of Cl79 per slide was pipetted into a small (600,.U capacity) microfuge 
tube along with driver DNA. The driver DNA used in this instance was autoclaved 
salmon sperm DNA; a ratio of75:1 driver:cosmid DNA was used. The driver DNA 
and the probe DNA were then desiccated to zero volume in a "speedivac". (It should 
be noted that fluorescein is light-sensitive and as such should be exposed to only the 
minimal amount of light). When this reduction in volume had been achieved I 0~1 
per slide of Kevil's hybridisation mix was added to the tube. The tube was quickly 
vortexed and then centrifuged at 12000g for~ 20 seconds in a microfuge. The DNA 
was then be denatured by heating for 5 minutes in a thermal cycler, (various 
'i 
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temperatures, 70°C or 94°C, were tested using this method). The tube was removed 
from the machine at the end of the cycle and placed immediately on ice for 1 minute. 
The probe was then allowed to pre-reassociate for 30 minutes at 37°C. The 
chromosomal DNA on the slides was then denatured to correspond to the completion 
of the 30 minute incubation period. To denature the slides they were placed for 3 
minutes in the 70% fonnamide/2xSSC which had been pre-warmed to 70°C. V.'hile 
slides were in the Coplin jar the tube was vortexed and quickly centrifuged at 
12000g for r::: 20 seconds in a microfuge. The slides were removed from the Coplin 
jar and, without allowing them to dry, lOft] of the tube contents was applied to the 
centre of each slide. The slides were then covered immediately with a 22 x 22mm 
glass coverslip which was secured with a spot of clear nail varnish. The slides were 
put into a sealed plastic container with a 2xSSC saturated atmosphere and hybridised 
overnight (16 hours) at 37°C. 
DAY2: 
I. Two Coplin jars containing 50ml aliquots of 50% formamide/2xSSC were heated 
in a waterbath to 42°C. When this temperature was attained, the sealed container 
with slides in it was removed from the incubator. The slides were taken out of the 
container and the coverslips removed. The spot of nail varnish which secured the 
coverslips should also slide off, if it did not the edge of a scalpel blade was used to 
chip the varnish off the slide and the coverslip then removed. 
2. After the coverslips had been removed the slides were washed 'With agitation as 
follows: 
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Twice for I 0 minutes in 50% formamide/2xSSC at 42°C, twice for 5 minutes in 
2xSSC at room temperature and once for 5 minutes in IxSSC at room temperature. 
3. The slides were then rinsed twice for 2 minutes in PBS at room temperature and 
drained briefly but not allowed to dry. 
4. The chromosomes were counter-stained with the application of 20~ of anti-fade 
solution with propidium iodide to each slide. 
5. The slide was then covered with a 22 x 50nun coverslip, and at this stage the slide 
was ready to view under a fluorescent microscope at the appropriate wavelength. 
NB slides were kept in the dark at 4°C, as colour of signal fades significantly within 
48 hours if exposed at room temperature. 
lll.4.i).b. Protocol# 2 in situ hybridjsation ofCI79labelled with Biotin-16-dUIP 
This labelled probe was received from the Department of Cytogenetics and 
Molecular Genetics at the Adelaide Women's and Children's Hospital. The protocol 
used was the one supplied by that Department. 
DAY I: 
I. Steps 1-3 from day I protocol #I were repeated. 
2. Again the probe DNA was denatured prior to the denaturation of chromosomal 
DNA. The optimal ratio of driver:probe DNA was determined by the Adelaide 
laboratory to be 400:1. To accomplish this ratio 20ng of probe and 8000ng of driver 
COT-I DNA (COT-I) per slide were pipetted into a small microfuge tube and co-
desiccated to zero volume in a "speedivac, as before. 
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3. Kevil's hybridisation mixture (IOf!Vsiide) was added to the tube, which was then 
vortexed and quickly spun in a microfuge as in step 4 protocol #I (DAY!). 
4. The tube contents were denatured by placing the tube in a polystyrene foam 
surround and floating it in a water bath at 70°C for 5 minutes. It was then 
immediately placed on ice for 1 minute, after which time the tube was incubated at 
37'C for 40-90 minutes. The chromosomal DNA was denatured on the slides in 
70% formamide/2xSSC as in step 4 protocol #! (DAY I) and IOfll of denatured 
probe was applied to each slide and covered as before. The slides were again 
hybridised overnight at 37'C in a 2xSSC saturated atmosphere. 
DAY2: 
1. The slides were removed from the sealed container and steps 1~2 from protocol #l 
(DAY 2) were repeated. 
2. This probe was labelled with biotin and it was therefore necessary to incubate the 
slides with an antibody conjugated to fluorescein or an enzyme to detect 
hybridisation signal in this protocol. In this case streptavidin-FITC was used; 
streptavidin has a high binding affinity to biotin and it was conjugated to fluorescein. 
3. Before the streptavidin-FITC was added, the slides were first treated at room 
temperature as follows: 
The slides were rinsed for 3 minutes in 4xSSC/0.05% Tween 20® in a Coplin jar at 
room temperature. The slides were pre-incubated in 4xSSC/I% BSA (IOOfll per 
slide under lab film) for 10 minutes (2xSSC saturated atmosphere). 
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4. The slides were kept in the dark as soon as the fluorescein conjugate was applied 
and they were not allowed to dry out. Drying was prevented by keeping slides in a 
2xSSC saturated atmosphere during incubation periods. The streptavidin-FITC was 
made up to a dilution of I :250 in PBS, 60f1l per slide (under lab film) was applied to 
each slide, and the slides incubated at room temperature for 20 minutes. 
5. The slides were washed and rinsed as follows: 
Twice for 5 minutes in 4xS5C/0.05%Tween 2000 (lOOfll per slide under lab fihn), 
then once for 2 minutes in 2xSSC and finally twice for 2 minutes in PBS. 
6. The slides were then counter-stained and covered with coverslips as in steps 4 & 
5, protocol# I (DAY 2). 
lll.4.i).c. Protocol# 3 in situ hybridisation of C179 labelled with Di2oxjj:enjn-ll-
A number of detection methods were attempted with the Cl79 probe that was 
labelled with digoxigenin (DIG). These include fluorescent in situ hybridisation 
(FISH) using an antibody conjugated to FITC, and non-isotopic in situ hybridisation 
without the use of fluorescence. The first part of the protocol. for both types of 
detection was the same. 
DAY!: 
I. Steps 2-3 from day I protocol #I were repeated to RNase slides and the slides 
rinsed. 
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2. COT-I driver DNA and probe DNA were pi petted into a small microfuge tube and 
co-desiccated as before to zero volume. A number of driver:probe ratios were tried, 
they ranged from 16:1 to 500:1. 
3. Kevil's hybridisation mixture(! 0111 of per slide) was added to the tube and the tube 
was then quickly vortexed and centrifuged as before. 
4. The tube contents were denatured by floating it in a 70°C waterbath for 5 minutes, 
it was then placed on ice for 1 minute to ensure that the DNA remained single-
stranded. 
5. The probe DNA pre-reassociated by leaving it to stand at 37'C for I 0-90 minutes. 
6. At the end of this time the tube was vortexed and centrifuged as before and I 0111 
of probe mixture was applied to each slide. 
7. The mixture was covered with a 22 x 22mm glass coverslip and all the edges of 
the coverslip and slide were sealed with rubber cement. 
8. The rubber cement was allowed to dry for 5-15 minutes, and the chromosomal 
DNA was then denatured by heating the slide on the upper surface of a metal plate in 
a waterbath at 70-75'C for 10 minutes. (The metal plate was positioned on the 
surface of the water and prevented the slide from becoming immersed). 
9. The slide was removed from the waterbath and incubated overnight at 37°C in a 
2xSSC saturated environment. 
DAY2: 
J • Rubber cement was removed from around the coverslip with forceps and the cover 
slip was then allowed to slide off the slide as it was washed. 
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2. Slides were washed at 37°C with agitation as follows: 
Twice for 6 minutes in 2xSSC, twice for 7 minutes in lxSSC and then once for 8 
minutes in O.lxSSC. 
3. After washes the detection method of choice was followed. 
)IJ.4.i).c.(ll). Anti-di~oxi2enin horse radish peroxidase Q'OD) or (g.-DIG HRP) 
detection 
l. Each slide received 7.5 units of a-DIG HRP in TBS to a total volume of70Jll per 
slide, (3.51!1 of a-DIG HRP in 66.51!1 of TBS). The slides were incohated in this 
solution for 1 hour at 37°C, in a 2xSSC saturated environment. 
2. The slides were then washed twice for 5 minutes in TBS. 
3. To detect the horse radish peroxidase a colour solution was applied to the slides. 
The colour solution was made from the following reagents; 6.0mg of diamino-
benzidine solution (DAB), !Om! ofTBS and lOJll ofH20 2 (30%). It was mixed and 
then filtered through a sheet of fluted filter paper on to the slides. The solution was 
never prepared in advance because it is extremely heat and light sensitive, any 
surplus was discarded. The colour solution was left on the slides for I 0 minutes and 
then removed by three I minute washes with agitation in TBS at room temperature. 
4. The slides were most often counter-stained in 3% Giemsa solution for:- 10-15 
minutes. Alternatively, haematoxylin followed by Scott's tap water was used as a 
counterstain (see ll.2. Reagents in use). 
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5. Each slide was air-dried and mounted in DePeX mounting ~:._,edia, then covered 
with a glass 22 x 50mm coverslip. When the mounting media was dry slides were 
viewed under a light microscope. 
Ill.4.i).c.!b). Anti-di~oxigenin fluorescein (lx-D!G FITC) 
I. After tbe slides had been washed as in step 3 (DAY 2) tbey were rinsed for 3 
minutes in 4xSSC/0.05%Tween 20® in a Coplin jar at room temperature. The slides 
were then pre-incubated (in a 2xSSC saturated atmosphere) for 10 minutes in 
4xSSC/l% BSA (I 00~1 per slide under lab film). 
2. The slides were kept in tbe dark from this step on. The antibody used for 
detection, a-DIG FITC, was made up to a dilution of I :250 in PBS and applied to 
the slides (60~1 per slide under lab film), tbey were tben incubated for 20 minutes in 
a 2xSSC atmosphere at room temperature. 
3. The slides were washed and rinsed as follows: 
Twice washed with agitation for 5 minutes in 4xSSC/0.05%Tween 20® (100~1 per 
slide under lab film), then rinsed once in 2xSSC for 2 minutes and twice in PBS for 2 
minutes. 
4. The slides were counter-stained and coverslips applied as in steps 4 & 5, protocol 
#I (DAY2). 
IIL4,i),d, In situ hybridisation ofOocor probe labelled with DIG-11-dUTP 
This probe was hybridised in acrordance with manufacturer's recommendations. 
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DAY!: 
I. The slides were pre-treated in 2xSSC for 30 minutes at 37'C. The slides were 
then dehydrated through a series of ethanols (70%, 80%, Md 100%) at room 
temperature for 2 minutes each, after which they were stood upright and allowed to 
dry. 
2. The slides were denatured in 70% formamide/2xSSC at 70'C for 2 minutes then 
dehydrated through a series of ethanols (70%, 80%, and 100%) at -20'C for 2 
minutes each. Again the slides were stood upright and allowed to dry. 
3. The probe was pre-wanned at 37°C for 5 minutes, it was imperative that this probe 
was not heat denatured. 
4. The oro be which was mixed with a hybridisation solution prior to purchase, was 
applied (I O;tl to each slide) and covered with a 22 x 22mm glass coverslip which 
was tht:n sealed with rubber cement. 
5. The slides were hybridised overnight (16 hours), in a humidified chamber at 37'C. 
DAY2: 
I. The slides were washed in 50% formamide/2xSSC (pH 7.0) at 43'C for 
IS minutes, followed by an 8 minute wash in 2xSSC at 37'C. The slides were then 
transferred to PBS at room temperature where detection could proceed. 
2. Full strength anti-digoxigenin FITC was applied to slides (60~1 per slide) and 
they were incubated in a dark humidified chamber at 37'C for 5-30 minutes. 
3. Slides were then rinsed three times for 1 minute in PBS at room temperature. 
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4. The chromosomes were counter~stained in antifade mounting medium with 
propidium iodide, at a final concentration of0.3 fig/mi. 
III.4.ii). Amplification steps for in situ hybrjdjsatjon 
AII of the hybridisation protocols #2-4 can make use of amplification steps in order 
to amplify hybridisation signal. Instead of just one antibody being used, 2 or more 
steps were carried out. For example, rather than using just anti-digoxjgenin horse 
radish peroxidase for a 1-step detection, anti-digoxigenin fluorescein fall owed by 
anti-fluorescein horseradish peroxidase could be used. This amplification step can 
increase the intensity ofhybridisation signal. 
lll.4.iii). Enhancement ofDAB 
Hybridisation signal detected by the DAB colour reaction can also be intensified by 
the use of metals. At the end of the colour reaction and before washing in TBS, 
slides were rinsed in 2% CuS04(aq) at room temperature for 2 minutes. This 
increased the precipitation signal of DAB. 
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111.5. MjcrosCOIIY 
III.5.i). Fluorescent microscope for fluQrescejn/PI 
To view slides counterstained with propidium iodide a Leitz fluorescent microscope 
was used at a wavelength of 595nm, this wavelength allowed the simultaneous 
visualisation of both propidium iodide and fluorescein-12-dUTP. 
III.5.ii). Confocal scannini: microscupe 
Slides which were stained by fluorescent reagents could be viewed under a confocal 
scanning microscope. This microscope was more sensitive than a standard 
fluorescent one and it can therefore detect hybridisation signal with greater clarity. 
The microscope used was at the Electron Microscopy Centre at the University of 
Western Australia and was operated by Dr. Ulrich Seydel. 
III.S.iij). Li~hl microscope for HRPIDAB/Giemsa 
Slides counter-stained with Giemsa were viewed under a Leitz light microscope at 
high power with oil immersion. 
II1,5,iy). Geneyjsion used to produce jmar.:es ofli2ht microscqpe slides 
A light microscope at the Cytogenetics Department of SHLS (WA) is connected via 
a video camera to a software package called "Genevision". This package allowed 
images from microscope slides at high power to be transferred on to a computer 
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screen so that karyotyping could be done. Print outs from "Genevision" of 
hybridised metaphase spreads are shown in the results section. 
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IV. Results 
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IV. Results 
IV.l. Isolation ofC!79 [rom bacteria 
IV.l.D. Isolation of CI79 DNA from bacteria and determination ofthe size 
As previously stated (p44), cosmid CI79 arrived from the U.K. as an agar stab 
culture, since no information was provided on the species or strain ofthe bacterium it 
was treated as Escherichia coli (E. coli) one of the more common types of bacteria 
used for plasmid and cosmid transfection. The Mini-preparation of C 179 produced a 
visible pellet of DNA and the cosmid DNA thus isolated by this method was run on a 
mini-gel against markers of known size. It was determined that the DNA isolated 
was around 40kb in size when compared to markers of known molecular weight. 
IV.l.jj). Maxi-pre])aration of cosmid Cl 79 
After C 179 was successfully isolated from a small scale preparation, a maxi-
preparation was set up. The maxi-preparation yielded 16 Eppendorf tubes of DNA at 
various w/v concentrations. Half of the tubes were sent to the Department of 
Cytogenetics and Molecular Genetics at Adelaide Women's and Children's Hospital, 
the remainder were rdained trJ be labelled and used in in situ hybridisation reactions. 
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IV.2. Probe labelline 
IV.2.D. Concentration ofcosmjd DNA 
In order to label the probe the DNA concentration must first be determined, this was 
done by the absorbance method outlined in the Methods section. When a sample of 
CI 79 was tested by this method the following results were obtained. 
Table IV. 1 Concentration and purjty of cosmid DNA 
ABSORBANCE DNA PURITY CHECK FACTOR 50 
RATIO MODE 
wavelength 260nm 280nm RATIO 
concentration 
ref O.OOOA O.OOOA at wavelength 
260nm 
celll 0.055A 0.030A 1.831 = 2. 751!g/ml 
After a 1 in 2000 dilution the isolated cosmid DNA had a concentration of 
2.75JJ.g/ml; this figure was used in order to calculate the volume of DNA required for 
labelling reactions. 
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IY.2.ii). Labellin~ of C I 79 with di~oxigenjn lzy the random primed method 
A number of aliquots of DNA were labelled during the course of this research, and 
all were first tested to determine DNA concentration and purity as described above. 
The volume of DNA in solution which corresponded to lf1g was diluted to a final 
volume of I Ofll in ddH20 for each labelling reaction. Labelling of DNA with 
digoxigenin was confirmed as previously described (p54), using a nylon membrane 
with alkaline phosphatase to detect hybridisation. Figure IV.! shows an example of 
one such membrane. The dots represent two areas of hybridisation with the labelled 
cosmid DNA, they appeared after 10 minutes incubation and the reaction was 
stopped after 40 minutes (the signal remained visible on the membrane for a further 4 
months). 
IV.2.iji). Confinnation that the isolated probe was C179 
In addition to the request for information ac; to the nature of the bacterium supplied, 
the Newcastle (U.K.) group were also asked to provide a cosmid map and restriction 
digest information. To ensure that the DNA isolated was cosmid CI79 (and did not 
result from contamination with another cosmid or piasmid), a restriction digest of the 
cosmid was performed with 3 of the more common restriction enzymes, Bam HI, 
Eco Rl, and Hind III. The resulting mini~gel which consists of lanes 1~8 running 
from left to right is produced in figure IV.2. It shows that the uncut Cl79 in lane 3 
has three bands representing the three possible forms of DNA, these are:~ 
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(i) Double stranded circular DNA which has only one of the strands nicked, i.e., it 
travels slowly through the gel as a large circle of DNA. 
(ii) Double stranded circular DNA which has both strands nicked and moves through 
the gel more quickly as a linear strand of DNA. 
(iii) Double stranded circular DNA that has not been nicked, this form of DNA tends 
to constrict into a spherical form and migrates through agarose gels faster than either 
of the nicked DNA forms. 
Lanes 4-6 show the restriction digest of Cl79 with Bam HI, Eco RI & Hind III 
respectively. Lane 8 contains a DNA marker (1.-Pst 1) of known size. The results of 
a similar experiment were recently received from the U.K. and are shown in figure 
IV .3 as a southern blot of C 179 digested by Hind Ill. Although this digest cannot be 
directly compared to those shown in figure IV.2. the size of the bands which result 
from the Cl79 Hind Ill lane were of equivalent size when compared to!V.3. The 
photograph (IV.3) was supplied by the laboratory which donated the probe, The 
Department of Human Genetics at the University of Newcastle Upon Tyne (UK} 
• 
! 
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Figure IV. 1 : 
Membrane to check labelling of Cl79 probe with digoxigenin, dots represent areas 
ofhybridisation with labelled probe. 
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Figure IV.2: 
Restriction digest of C 179 cut with the restriction enzymes, Bam HI, Eco RI and 
Hind III. Gel lanes are loaded as follows: 
LANE CONTENTS & NUMBER 
nil nil uncut C179 · ; ··C179 Cl79 nil A.-Pst 1 
with 
' 
·.with ' with 
Bam HI Eco RI Hind ill 
1 2 3 4 5 6 7 8 
Fi~nJre IV.3: 
Southern blot from the U.K. of C 179 digested with Hind III as marked. 
ltBtW(;fJ'JftL! 
i " 
.... r: 
I ~ : 
. ' . 
' 
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IV.3. Preparation of metaphase chromosome spreads 
IV.3.i). Cbromo~·ome spread production and quality 
Metaphase chromosome spreads were processed at the Cytogenetics Department of 
SfiLS. Although there was insufficient time during this project to perform in situ 
hybridisation on all of them, over 100 specimens were cultured and processed. All 
specimens have been karyotyped from synchronised cultures, and many high 
resolution karyotypes have also been performed by this department. The specimens 
set up yielded high quality metaphase chromosomes which banded successfully. 
IV.3.ii). Results ofcyto~enetjc karyotyping of DGS patients 
As was expected, few of the suspected DGS patients showed a microdeletion of 
chromosome 22qll cytogenetically (Carey et a/., 1992), however to date two 
patients in the sturfy show monosomy 22q 11 from high resolution studies. The 
resulting metapha•,e spread and karyotype of the synchronised culture and the 
metaphase spread and ideogram of the high resolution culture is shown from one of 
these patients in figures IV.4-IV.7. No apparent aberration is observed from the 
synchronised culture but monosomy 22qll is detected on the high resolution slide 
(see figures IV.6, arrows indicate both 22 chromosomes and Figure IV.7 which 
shows a partial karyotype of the chromosomes). The work on these karyotypes was 
performed by the Cytogenetics Department at SHLS. 
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Fi2ure IV.3: 
Metaphase spread of synchronised peripheral whole blood culture. 
/ 
... 
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Figure IV.5: 
Karyotype of synchronised peripheral whole blood culture, shown in figure IV.4. 
2 3 4 5 
6 7 8 9 18 11 12 
1.3 14 15 16 17 18 
28 21 22 X Y 
N.Me:LS Tlssua:B 
: KH slldea:4 Y:96.8 X:58.7 Check:LJU 
~~~~=~4=6~,~~----------~--~-----------------------18=24-94 ____ ~ 
84 
Figure IV.6: 
Metaphase spread of high resolution (HRS) peripheral whole blood culture. 
10/24/94 30604.ME1 30604 LS BL KH HR2 99. 
46,XY,delC22)Cq11.2) 
. ' . 
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Figure IV.7: 
High resolution partial karyotype of patient displaying monosomy 22q 11, with 
accompanying ideogram of chromosome 22. 
_11.22 
• • 
-
-
"ame: LS 
,11.22 ~ 
22 
.. ~q11.22 deleted 
-
-
-
Tissue:BL 
slidea: v: x: Check: 
46, >1:'1, de 1 ( 22) ( q~1..::1:..:.• ..::2:...;>:.._..._~-~--~-~-~-9-t:T-94 -~--' 
.. 
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!V.4. In situ bybridisation 
IY.4.Q.- In siftl bybridisation with Fluorocreen labelling 
All attempts at hybridisation using this method failed to show hybridisation signal. 
The metaphase chromosomes stained well with propidium iodide and were clearly 
visible under the fluorescent microscope at A = 595nm. There also was no 
background signal detected by this method. Fluorogreen from the same batch had 
been used to label a probe by this method at the Department of Haemotology at__ 
Royal Perth Hospital, but this probe labelling was also unsuccessful. It was 
determined therefore that this method would not be pursued further, both because no 
new Fluorogreen was available and the random primed method with digoxigenin 
labelling was proving to be reliable. 
lV.4.ii). In situ hybridisation with bjotjn labelling 
As previously noted, a sample ofC179 was sent to the Department of Cytogenetics 
and Molecular Biology at the Adelaide Women's and Children's Hospital. This 
sample was sent to the laboratory primarily to verify that the cosmid isolated in Perth 
was Cl79, and that it did in fact hybridise to chromosome 22qll. The reason for the 
choice of this particular laboratory was it's past success in using a cosmid probe for 
chromosome 22qll donated by the Newcastle group (U.K.), and it also has several 
years experience of in situ hybridisation. In Adelaide it was confirmed by 
.fluorescent in situ hybridisation (FISH) that C 179 cosmid hybridised to chromosome 
i 
K-
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22q 11. This confirmation, and the results of the restriction digest and southern blot, 
suggest that the correct cosmid was isolated by maxi-preparation. A sample of 
biotinylated Cl79 probe was returned from Adelaide for use in the present study. 
Several attempts were made to undertake FISH with this probe using a sightly 
modified version of the Adelaide protocol, however none of the metaphase 
chromosome spreads showed hybridisation signal, although fluorescent background 
signal was apparent on many of the slides. 
IV.4.iii). In sUu hybridisation with djgoxigeojn Jabellinfi 
IV.4.iii).a. Horse radish peroxidase and DAB conjugated to DIG 
Due to a lack of success with FISH using Cl79 labelled with Fluorogreen and biotin, 
an alternative label and detection system was investigated. The C179 probe was 
labelled with digoxigenin by the random primed method and tested for correct 
labelling. When it was confinned that this probe was labelled with digoxigenin, in 
situ hybridisation was undertaken. Horse radish peroxidase was used instead of 
fluorescein to detect the reporter molecule, and hybridisation signal was then 
visualised with diaminobenzidine (DAB). Several hybridisation experiments using 
this method resulted in apparent hybridisation of Cl79 to a G-group chromosome, 
presumably chromosome 22. A summary of some of these results are outlined in 
table IV.2 which is accompanied by figures IV.8-IV.20. Double arrows indicate 
regions of apparent hybridisation on G-group chromosomes, and single arrows point 
to the other G-group chromosomes where no signal is visible. There are no arrows 
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on metaphase spreads which show excessive non-specific signal. Unless indicated, 
patients all display phenotypes consistent with DGS. 
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Table IV.2. Summar; ofjn situ hybridjsation results 
PatientiD fig# Hybridisation Comments 
I~ on 1 0-chromosome Signal was strong 
34924MAP 8 marked by double arrow some background visible 
1 'V on 1 G-chromosome Signal visible under 
36153MTC 9 marked by double arrow microscope -dark on print 
I V on 1 G-chromosome Poor chromosome 
36154MRO 10 marked by double arrow morphology 
I~ on 1 G-chromosome Mother of patient in figs 
35181M LS 11 marked by double arrow IV.4-JV.7; 
only subtle signs ofDGS 
I -v on 2 G-chromosomes Signal and chromosomes 
36019MNP 12 marked by double arrows pale 
I~ on 2 G-chromosomes Chromosomes pale 
35976M SC 13 marked by double arrows but signal present 
'i on 2 G-chromosomes Morphology of 
36055MJH 14 marked by double arrows chromosomes poor 
I -v on 2 G-chromosomes Signal and chromosomes 
35990MAB 15 marked by double arrows pale 
I~ on 2 G-chromosomes Signal and chromosomes 
44444M 16 marked by double arrows pale 
(control) 
'I on 2 G-chromosomes Signal was visible under 
36159MAA 17 marked by double arrows microscope -dark on print 
'i on 2 G-chromosomes Chromosomes dark 
35945MCA 18 marked by double arrows but signal present 
36225MJP 19 No signal visible 4X nonnal strength DAB 
Excessive signal on all Impossible to comment on 
35506M NT 20 chromosomes G-group chromosomes 
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Fi~mre IV.8: 
Metaphase spread of patient 34924M AP, shows hybridisation signal detected with 
the use of anti-DIG HRP and visualised with DAB, on 1 G-group chromosome 
(marked with double arrows). 
09/30/9~ 34924M.ME1 34924M AP BL MM 4 103.2 4 
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Figure IV.9: 
Metaphase spread of patient 36153M TC, hybridisation signal detected with the use 
of anti-DIG HRP and visualised with DAB, on 1 G-group chromosome (marked with 
double arrows). Counter-staining is dark, but signal was visible when viewed under 
the microscope. 
09/30/94 36153M.ME1 36153M TC BL MM 1 fil 
.. 
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Figure IV.lO: 
Metaphase spread of patient 36154M RO, hybridisation signal detected with the use 
of anti-DIG HRP and visualised with DAB, on 1 G-group chromosome (marked with 
double arrows). Counter-staining is dark and chromosome morphology is poor, 
however signal is clearly visible. 
09/30/94 36154M.ME2 36154M RO BL MM 1 fil sav 
. ' . 
. · 
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Figure IV .11 : 
Metaphase spread of patient 3 5181 M LS, hybridisation signal detected with the use 
of anti-DIG HRP and visualised with DAB, on 1 G-group chromosome (marked with 
double arrows). This culture was prepared from the mother of patient 30604 LS, 
who was shown to have monosomy 22q 11 by HRS karyotyping. 
09/30/94 35181M.ME3 35181 LS BL MM fil sav 
. . . 
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Figure IV.l2: 
Metaphase spread of patient 36019M NP, hybridisation signal detected with the use 
of anti-DIG HRP and visualised with DAB, on 2 G-group chromosomes (marked 
with double arrows). Hybridisation signal and chromosomes were pale due to 
shorter exposure time to counter-stain. 
09/30/94 36019M.ME2 36019M NP 8[ MM 1 fil sav 
• c • 
' 
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Fi~rnre IV.13: 
Metaphase spread of patient 35976M SC, hybridisation signal detected with the use 
of anti-DIG HRP and visualised with DAB, on 2 G-group chromosomes (marked 
with double arrows). Hybridisation signal and chromosomes were pale due to 
shorter exposure time to counter-stain. 
35976M.ME4 35976M SC BL MM 3 96.3 45.0 
.. 
• 
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Figure IV.14: 
Metaphase spread of patient 36055M IH, hybridisation signal detected with the use 
of anti-DIG HRP and visualised with DAB, on 2 G-group chromosomes (marked 
with double arrows). Hybridisation signal and chromosomes were pale and 
chromosome morphology was poor, tllis was probably caused by washing slides with 
too high a stringency. 
09/30/94 36055M.KA1 36055M IH BL MM 103.9 44. 
• < • 
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Figure IV.15: 
Metaphase spread of patient 35990M AB, hybridisation signal detected with the use 
of anti-DIG HRP and visualised with DAB, on 2 G-group chromosomes (marked 
with double arrows). Hybridisation signal was pale but visible when viewed under 
the light microscope; hybridisation signal was also detected on 2 chromosomes from 
this patient with the confocal microscope. 
09/30/94 35990M . ME1 35990M AB BL MM 1 109 . 0 48 . 3 
71 
.· 
98 
Figure IV.16: 
Metaphase spread of control patient 44444M, hybridisation signal detected with the 
use of anti-DIG HRP and visualised with DAB, on 2 G-group chromosomes (marked 
with double arrows). Non-specific hybridisation signal was also seen on some 
chromosomes, this can be reduced by increasing stringency of washes and by 
altering probe:driver ratio 
~9/30/94 44444M.ME1 44444M CONTROL BL MM 100.9 44. 
• 
• 
• -~ . 
- .. . 
. ·
99 
Figure IV.17: 
Metaphase spread of patient 36159M AA, hybridisation signal detected with the use 
of anti-DIG HRP and visualised with DAB, on 2 G-group chromosomes (marked 
with double arrows). Hybridisation signal is distinctly visible on both chromatids of 
the two chromosomes marked. 
09/ 30/ 94 36159M . ME2 36159M AA BL MM 104.4 42 . 7 
• 
l 
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Figure IV.18: 
Metaphase spread of patient 35945M CA, hybridisation signal detected with the use 
of anti-DIG HRP and visualised with DAB, on 2 G-group chromosomes (marked 
with double anows). Hybridisation signal is dark on both chromosomes. 
19/30/94 35945M .MEl 35945M CA BL MM fil sav 
• 
' . 
,. 
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Figure IV.19: 
Metaphase spread of patient 36225M JP, no hybridisation signal was detected on the 
chromosomes. The strength of DAB was increased in order to increase hybridisation 
signal intensity, however this change darkened all chromosomes and distorted their 
morphology. 
09/30/94 36225M.ME2 36225M JP BL MM 1 fil sav 
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Figure IV.20: 
Metaphase spread of patient 35506M NT, a high degree of non-specific hybridisation 
signal was detected on all chromosomes. This amount of signal was due to a 
reduction in the driver:probe ratio and means that any signal detected on the G-group 
chromosomes is meaningless. 
09/30/94 35506M.ME1 35506M NT BL MM 3 fil sa~ 
• 
• 
• 
. . 
)03 
IV.4.iii).b. Fluorescein conjugated to DIG. 
Fluorescent in situ hybridisation was also performed on Cl79 labelled with 
digoxigenin. No hybridisation signal was detected using either 1- or 2-step 
amplification methods by fluorescent microscopy, however a signal was apparent on 
one metaphase when scaoned by a confocal microscope (see figure IV.21). Other 
metaphase spreads with obvious background signal present when viewed by this 
method revealed large amounts of cytoplasm covering chromosomes (see figures 
IV.22-IV.25). It can be presumed that excessive cytoplasm prevents the 
hybridisation of probe DNA to chromosomal DNA by acting as a physical barrier. 
Signal was also detected from interphase nuclei by this method (see figure IV.26), 
although it was not determined if this was hybridisation signal or background signal. 
All hybridisation and background signals on figures IV.21-IV.26 are indicated by 
arrows. 
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Figure IV.21 and IV. 22: 
IV .21. Shows metaphase spread with apparent signal on 2 chromosomes. 
IV.22. Non-specific signal shown. 
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FifWre IV.23 and IV. 24: 
IV.23. Shows metaphase spread with surrounding background signal. 
IV.24. Bright backgound signal shown. 
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Figure IV.25 and IV. 26: 
IV .25. Shows metaphase spread and surrounding interphase nuclei with signal. 
IV.26. Backgound signal outside interphase nuclei with pale signal inside 1 nucleus. 
. 
. 
! 
I 
; 
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IY.4.iv). In situ bybridisation with D22S75 Oncor pro~ 
D22S75 was purchased from Oncor, with sufficient probe supplied to hybridise 20 
slides. Using this probe fluorescent in situ hybridisation was carried out on three 
slides but since a hybridisation signal was not detected on any of these slides, and 
due to the expense of the cosmid probe (over $30 for each slide), it was decided that 
a more detailed protocol probably was required. After discussion with the 
manufacturer, two Australian research groups who have used this probe have agreed 
to supply their successful modified protocols, and on receipt of these protocols 
sufficient probe remains to process a further 17 slides. 
108 
Y. Discussion 
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V. Djscussjon 
V.I. Introductjon 
The detection of genetic disorders by the use of in situ hybridisation has been shown 
by numerous researchers to be a most effective method to confirm clinical diagnoses 
(Carey eta/., 1992). Although initially this technique has proved difficult to execute, 
once the requisite experimental conditions are optimised routine diagnosis is 
possible. Individual probes appear to have distinct optimal conditions for in situ 
hybridisation which further comr :~cates establislunent of the technique. This is 
particularly the case for wrique sequence probes, such as those used in the present 
study, which require highly specific experimental conditions in order to visualise 
signal without an excessive amount of non-specific signal. In the following 
discussion, aspects of in situ hybridisation which are necessary to successfully 
expedite its use will be addressed. 
V.2. Probe pre.paration 
V.2.i). The preparation of an agar stab culture 
Plasmids are small circular molecules of double-stranded DNA that occur naturally 
in both bacteria and yeast; they replicate as independent units as the host cell 
proliferates, This self-replication is exploited in molecular cloning (Alberts et a/., 
1983). Cosmids in their simplest form are modified plasmids that carry a copy of the 
DNA (cos) sequences required for packaging DNA into bacteriophage A. particles. 
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Cosmids carry an origin of replication and drug resistance markers so they can be 
introduced into bacterial vectors by standard transformation procedures and 
propagated as plasmids (Sambrook et a/., 1989, p. 3.5). The DGCR probe used in 
this study is a cosmid probe (Cl79), and it has an insert of DNA which is 
complementary to part of the DGCR. In order to clone this insert sequence the 
cosmid was transfected into a bacterial vector in which it could replicate. Cosmid 
probe C179 was received in a kanamycin~resistant bacterium as an agar stab culture 
from Professor J Bums group in the UK. In addition to this probe, similar cosmid 
probes from the U.K. group have been isolated from chromosome 22 libraries and 
digested with the restriction enzyme Hind III, with fragments then shotgunned into a 
Hind III digested vector to form cosmids (Wadey et a/., 1993). A photograph of 
Cl79 cut with Hind III was received from Bums eta/, (figure V.3). In order to label 
the cosmid for in situ hybridisation it must first be amplified and then isolated from 
the bacterial host. 
Y.2,ii). Yield ofcosmid DNA 
Experimental conditions effect both the yield and purity of cosmid DNA prepared by 
alkaline lysis (Sambrook et a/., 1989, p 1.25). To ensure a high yield of DNA, 
special care must be taken to remove all supernatant from the bacterial pellet and 
nucleic acid precipitate phases. Attention should also be paid to the particular 
temperature required at different stages of the reaction, e.g., if nucleic acids are 
centrifuged at 4 °C instead of room temperature, the sodium salt present in solution 
' t 
" 
' ' 
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may precipitate and become pelleted, thus causing contamination of the resultant 
DNA (Sambrook eta/., 1989, p 1.39). 
V.2.iii). The concentratjon of the isolated ffi.J"A 
The concentration (w/v) of the isolated DNA must be measured so that a known 
quantity of DNA can be labelled for in situ hybridisation. The concentration of DNA 
measured using the absorbence method will highlight experimental contaminants 
such as salts by yielding an abnonnal value. This method will not indicate the 
presence of contaminant DNA or the isolation of the incorrect cosmid, because it is 
unable to distinguish between different forms of DNA, or protein. For this reason it 
was necessary to perform a restriction digest on isolated C179, the results of which 
can be compared to the restriction digest of a pure sample of the probe. This method 
allows confirmation that the correct cosmid was isolated and jodicates its level of 
purity. If contaminant DNA is present, the restriction digest banding pattern will 
differ from that given by the pure probe. If this digest is not undertaken and 
contaminant DNA is labelled, hybridisation signals can occur on unexpected 
chromosomes giving confusing results and high levels of non-specific hybridisation. 
V.3. Probe labelling 
When it was confirmed that Cl79 had been isolated, probe labelling was carried out 
using three different methods. These are sununarised below: 
' 
' 
' ' 
' 1,-
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Y.3.i). Direct labellin2 
This probe labelling technique was attempted with FluorogreenTM (Amersham) a 
fluorescein-12-dUTP conjugate which can be attached directly on to either a plasmid, 
cosmid or YAC probe, by nick translation. The FISH carried out with directly 
labelled C 179 was unsuccessful, with no hybridisation or background signal 
detected. The absence of signal could be due to a number of reasons, including 
failure of the nick translation reaction to incorporate fluorescent nucleotide into the 
probe. However, without checking the probe labelling it cannot be assumed that 
Fluorogreen was conjugated to C179. If labelling of the probe was achieved and 
hybridisation did occur, it still may be difficult to detect signal. Directly labelled 
probes require no amplification steps to detect hybridisation signal in FISH, and this 
lack of amplification may be the reason why signal was not detected using probe 
labelled by this method. 
Y.3 .ii), Biotin labellin2 
Biotin labelling of C 179 was carried out by the Adelaide research group using the 
nick translation method. Probe labelling was not checked during the course of this 
study because the biotinylated probe was used to successfully delineate chromosome 
22q 11 in Adelaide by FISH. Although hybridisation signal was not visible when this 
probe was used in Perth, background signal was detected on some metaphases. This 
tends to suggest that the probe was labelled and that it was either a deficiency in 
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hybridisation or detection of hybridisation during another stage in the FISH reaction 
that prevented visualisation of the signal. 
V.3.iii). DIG labelling 
C 179 probe was labelled with digoxigenin-11-dUTP using the random primed 
method. This form of labelling was confirmed by detecting the hybridised probe on 
a nylon membrane with the enzyme alkaline phosphatase. Digoxigenin-11-dUTP 
(DIG) labelling proved to be very successful and it was straightforward to perform 
the labelling of the probe and to check this labelling. Hybridisation signal from ISH 
experiments was detected in each of the several batches of probe labelled by this 
method. 
V.4. Slide preparation 
Slide age and condition are among the numerous factors which effect the overall 
quality of chromosome metaphase spreads. Only good quality slides are used at the 
Cytogenetics Department at SHLS, each batch of slides is dated on arrival at the 
laboratory and those which are not used within six months of receipt are discarded. 
Even though the slides are clean when purchased, they are further cleaned by soaking 
in methanol, which ensures that when the cell suspension is dropped on to the slide it 
spreads evenly and is not affected by contaminant debris either on the slide or arising 
from the cell preparation. Excessive ammmts of cytoplasm can be a particular 
problem encountered in the production of metaphase spreads, and many innovative 
1 
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,echniques have been employed in order to reduce the amount of cytoplasm around 
cells. The method which seemed most efficient in decreasing unwanted cytoplasm 
was recommended by the Cytogenetics and Molecular Genetics Department at 
Adelaide Women's and Children's Hospital (E. Baker, personal correspondence). 
She suggested that, after cleaning, slides should be soaked in absolute ethanol at 
room temperature and then dipped into luke warm distilled water before the cell 
suspension is dropped on to the wet slides held at an angle of approximately 45° over 
a water bath at 50°C, This technique proved most helpful when fixed cell suspension 
had been stored at 4°C or -20°C for extended periods after harvesting of the cells. 
Slides used for in situ hybridisation require different conditions prior to use to those 
dropped for synchronised karyotyping with G-banding. Slides are not baked at 60'C 
overnight to artificially age chromosomes, instead those dropped for in situ 
hybridisation reactions are stored at room temperature, because baking slides can 
decrease the hybridisation signal. It. has also been noted that slides which are stored 
in dry conditions (in a desiccator) at room temperature produce a better hyhridisation 
signal (Lisa Robson, Cytogenetics Dept. Carnperdown Children's Hospital NSW, 
personal correspondence). Slides were usually employed in t.'>is study 1-5 days after 
dropping, however in most instances it is recommended that slides be used within a 
30 day period after dropping. If the cell suspension is not dropped immediately after 
processing it can be stored at 4°C or -20°C. Unfortunately it was observed that 
hybridisation may be hindered by increased amounts of cytoplasm surrounding tl10se 
' 
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cells which have been stored in this way. Although there are techniques to reduce 
this problem, it is advisable to perfonn ISH on cells as soon as possible after they are 
processed. 
V.5. In situ bybridisation 
The variation of in situ hybridisation protocols found in this study, and from 
laboratory to laboratory, reflects the common difficulty in establishing the technique. 
Even though the use of ISH is becoming more widespread in molecular biology, as 
Stahl & Baskin (1993) point out ISH is essentially a histochemical method and, as 
such, not only requires 'getting it to work' but also verifYing that 'it is working 
properly'. Concerns of signal specificity, sensitivity, resolution and controls must be 
addressed in order to usc ISH as a diagnostic test. Although some degree of success 
was accomplished with re,r.;pect to the use of in situ hybridisation in the present study, 
further detailed investigation is needed in the optimisation of the procedure. Specific 
hybridisation signal detection tiiid t1c reduction of background signal must be 
improved to make ISH a viable diagnostic test in the detection of DGS and related 
microdeletions. However some evidence from this study suggests that ISH will 
provide a valuable test for DGS. For example, figure IV.ll shows a mother with an 
apparent 22qll deletion, detected by ISH; susequently her son was also shown to 
have this deletion by HRS karyotype analysis (see figures IV.4-IV.7). An infant who 
was shown to have a microdeletion of chromosome 22qll with ISH, using a DIG-
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labelled Cl79, has since died as the result of complications due to VSD cardiac 
disease, post mortem examination revealed classic symptoms of DGS. 
The use of a digoxigenin labelled probe visualised by anti-digoxigenin HRP and 
DAB allowed the use of a light microscope rather than a fluorescent instrument. 
This form of detection is preferable to fluorescent microscopy because the signal on 
slides is pennanent. Thus, they can be hybridised immediately after the cell 
suspension is processed (which reduces interference from cytoplasm and 
concomitantly increases signal intensity) and then stored for analysis at a later time. 
One of the major disadvantages with this detection method is, however, that after 
hybridisation when chromosomes are counterstained and mounted they cannot be 
banded to identifY individual chromosomes. This can be overcome by the use of 
anoL1.er probe which is specific to the chromosome of interest, e.g., towards the end 
of the study a stab culture containing a probe which is specific for the telomeric 
region of chromosome 22 was made available by the Newcastle upon Tyne group. 
The probe was prepared from a kanamycin-resistant bacterium as previously 
described and run on a mini-gel to assess the purity of the isolated DNA (see 
Appendix I. figure VII .I). The probe has been stored at this stage and with further 
purification and labelling will be available for future use as another control. 
Conversely, FISH has the advantage over other forms of non-isotopic in situ 
hybridisation because it allows the Q-banding of hybridised chromosomes which 
enables their rapid identification. Unfortunately, it is not however as simple to detect 
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a FISH signal using a fluorescent microscope as it is to detect DAB signal on the 
light microscope. For this reason, many investigators use confocal laser scanning 
microscopy or cooled CCD cameras in order to detect signal from FISH and identifY 
individual chromosomes (Stahl and Baskin, 1993). 
V.6. Conclusions and future investigations 
The purpose of the present study was to explore the various possible techniques for 
the detection of hybridisation signal in non-isotopic in situ hybridisation, and to 
compare them with cytogenetic techniques using a probe specific for chromosome 
22q 11. Variability exists at every stage of the ISH reaction. Investigators must 
deduce what type of isolation, l8belling, hybridisation and detection protocols are 
appropriate for use with each specific probe. Not only must hybridisation signal be 
maximised and background signal minimised, but chromosome morphology has to 
be retained in order to identify which chromosomes actually have signal. This fr. ... tor 
conveys both advantages and disadvantages. For example, when the stringency of 
the washing solutions is increased by raising the fonnamide concentration, or by 
increasing the temperature and decreasing the concentration of sse, non~specific 
signal is reduced. However, changes of this nature in the protocol also have an 
adverse effect on chromosome morphology. Although all ISH protocols are based 
on the same principles, it is only by investigative trial and error that optimal 
conditions for ISH with specific probes and reagents can be achieved. During the 
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course of this study several protocols were tried with two probes in order to achieve 
hybridisation signal on metaphase chromosome spreads. 
It is envisaged that the information obtained in this study regarding the degree of 
success achieved with each of the experimental protocols tested will help future 
researchers who wish to use the probe. Over 100 patients were examined and bled as 
part of this study at Princess Margaret Hospital for Children (WA). All of these 
samples have been cultured and processed at the Cytogenetics Department of SHLS, 
and are now ready for ISH studies. An amniotic fluid sample and fetal tissue 
samples were also processed, then cryogenically treated and stored at -70°C for 
future investigation into the use of ISH for DGS. Results of these continuing studies 
will further advance our understanding of disorders such as DGS which display 
marked genetic heterogeneity, and as a result the counselling of affected individuals 
and their families should improve. 
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Appendix I 
Figure VII.1: Mini-gel resulting from maxi-preparation of cosmid probe specific for 
telomeric region of chromosome 22: 
Only lanes whose wells were loaded are numbered. Lane 1 is at the left hand side of 
the gel. Lanes 1-6 all contain 1J.Ll of cosmid probe and 1J.Ll of loading buffer, lane 7 
contains 1 OJ.Ll of cosmid probe and 2J.Ll of loading buffer and lane 8 was loaded with 
A.-Pstl. With further purification and labelling this probe could be used to identify 
chromosome 22. 
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Appendix ll 
The clinical research proposal for this study by Dr. Sharon Worthington, Princess 
Margaret Hospital for Children, W A. 
/ 
TITLE: THE CLIN!CAL; AND MOLECULAR DNA STUDY OF FAMILIAL 
CONGENTT AL HEART DISEASE 
AIMS: 
M3inaim: 
Specific aims: 
To investigate chromosome 22q II in patients and their families with CATCH 
22 disorders. ' 
I. To explore in detail the clinical spectrum of the individual syndromes 
embraced by the acronym CATCH 22. 
2. To explore the inheritance pattern ofthese disorders. 
3. To determine the prevalence of these conditions in the West Australian 
population. 
4. To provide more accurate data about the natural history of these 
disorders upon which to base genetic couselling for a specific group of 
heart defects. 
BACKGROUND 
The incidence of congenital heart disease(CHD) is approximately one percent of live births(!). 
Recent advances in cardiac surgery have resulted in long term survival of patients with complex 
CHD into adulthood. As a consequence there has been increased interest into the genetics of 
CHD. For the patients, their parents and extended families the recurrence risks and the 
possibility of prenatal diagnosis are important issues. 
Recurrence risks for CHD depend upon the mode of inheritance. Chromosomal abnormalities 
occur in twelve percent of CHD whereas three percent of CIID is due to classical Mendelian 
gene effects with recurrence risks of up to 50 percent(!). In most types of CHD however, the 
inheritance pattern is complex and is assumed to be of the multifactorial type with recurrence 
risks of3-5 percent depending on the type of lesion(!). This model assumes that the cause of 
the defect is due to the effects of several genes which are modulated by environmental factors, 
but it does not adequately explain the higher risks for some farru1ies ofCHD or the increased risk 
for specific anatomic defects such as obstructive lesions ofthe left side of the heart(2). 
CIID may be associated with exiracardiac manifestations as part of an identifiable malformation 
syndrome. In 1981 an association was noted between abnormalities of chromosome 22 and the 
DiGeorge Sequence(DGS)(3), Subsequent investigations have shown deletions of22qll at the 
DiGeorge Critical region(DGCR) in 83 percent of cases ofDGS(4). It has been postulated that 
these genes may play a role in neural crest cell migration which may be critical to the 
development of the normal conotruncus(S) with deletions resulting in CHD. This theory is 
supported by evidence of teratogenic· actiori of tretinoin which can produce very similar fetal 
defects(6). 
Submicroscopic deletions of chromosome 22q 11 have been associated with other syndromes 
such as Vela-Cardia-Facial Syndrome(VCFS) in 65-70 percent of cases(4), Conotruncal 
Anomaly Face Syndrome(CTF A) in 10-30 percent of cases(?), and the CHARGE association. 
These syndromes share common features(see table 1) and the acronym CATCH 22 (Cardiac, 
Abnormal facies, Thymic hypoplasia, Cleft palate and Hypocalcemia) has been coined to 
encompass this group of disorders associated with deletions of chromosome 22(8). 
Nonsyndromal CHD has also been associated with deletions of chromosome 22q 11. Patients 
with conotrucal defects, a cardiac defect which is overrepresented in the CATCH 22 disorders, 
have deletions of chromosome 22q 11 in 29 percent of cases(9). Deletions of chromosome 
22qll also occur in familial CHD(IO). 
Recurrence risks for these disorders vary from one to fifty percent and is dependent upon the 
inherited pattern, gene deletions or other chromosomal abnormality and other causes such as 
drugs. Counselling for patients with DGS and VCFS where a chromosome 22q II deletion is 
present in both the child and one of the parents is for an autosomal dominant inheritance with a 
recurrence risk of 50 percent. The risk is negligible if the parents are definitely unaffected. 
Genetic counselling of these disorders is limited by difficulties in diagnosis and lack of 
knowledge of the mode of inheritance of these disorders. Identification of patients with the 
CHARGE association and VCFS can be difficult because of the variability of these conditions 
and they are thus commonly underdiagnosed(ll). Cases reported in the literature thus far have 
come from only a few centres and have been identified through craniofacial centres or genetic 
units. 
In Western Australia there is a centralised service for the treatment of cardiac defects which 
would be ideal to study the population for the prevalence and natural course of these disorders. 
In the proposed study we intend to identifY families with the CATCH 22 disorders in WA from 
the Birth Defects Registry and from the cardiology department and investigate chromosome 
22qll. 
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MECHANISMS FOR PHENOT,YPE-GENOTYPE CORRELATIONS 
The mechanism of inheritance of these disorders has not been established. There is a wide 
spectrum of clinical manifestations with the potential for more severe birth defects occurring 
wi(h future generations(9). Numerous mechanisms have been postulated to explain these 
manifestations. Schmickel suggests tha.t DGS is a contiguous gene syndrome with hemizygosity 
for several genes resulting from the loss of multiple single genes in a small deletion(13). 
Contiguous genes are genes which are physically adjacent on a chromosome but are otherwise 
unrelate'd. A broad spectrum of clinical abnonnalities occur due to the wide range of molecular 
defects caused by the loss of these unrelated genes. Tills concept can explain interl'am.ilial 
differences but does not adequately explain differences in expression of these disorders between 
family members. 
The intrafarnilial differences could be due to parental mosaicism"with no mosaicism in the more 
severely affected child or an expanding mutation increasing in severity with each generation(4). 
The apparent increase in severity with a subsequent generation may be a result of selection bias 
of previous studies as they have not included children with the less severe manifestations of 
these disorders. Epigenic phenomena, that is genes at separate loci or envi~onmental factors 
could modifY the effects of those genes deleted resulting in intrafamilial variability( I OJ. The 
effects ofmatemal transmission and parental origin of deletions are other mechanisms that have 
not been adequately explored in these disorders. 
The proposed population based project will explore the clinical spectrum and the genetics of 
these disorders to establish more accurate genetic counselling and thus more meaningful 
prenatal diagnosis. 
LABORATORY METHODS 
Deletions of chromosome 22qll have been defined utilizing a number of molecular genetic 
techniques. Cytogenetic studies reveal chromosome abnormalities in only 15~2(1% of DGS 
cases. Molecular investigation with gene dosage analysis is a much more sensitiv~ technique but 
is very time consuming(14). Gene dose analysis involves using densitometry to quantatively 
analyse Southern blots to detennine the number of copies of a locus(identified by probes specific 
for that locus) that are present. Homozygosity occurs if there are two copies of the locus( these 
are unaffected individuals) and hemizygosity if only one copy is present( affected individuals). 
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Fluorescence in situ hybridization(FISH) has been shown to be a more efficieht and direct 
method for detection of22qll ~eletions in subjects with CATCH 22 disorders(l4,15). In situ 
hybridization is a technique used to identifY the chromosomal location of genes directly by 
hybridization of genomic or complementary DNA in situ to the DNA of a cytological 
preparation. This technique is currently being used to more accurately define the limits of the 
DCGR. For diagnostic purposes a probe specific for the areas of interest is labelled with an 
antibody and hybridised to its matchi~g DNA sequence on a cytological preparation from the 
patient. The preparation is counterstained with a dye which fluoresces and this is viewed using a 
fluorescence microscope. If a hybridisation signal is seen on only one of the chromosomes 22 
this is consist'ent with gene deletions in the 'region recognised by the probe. 
PROTOCOL 
I, ST!Y.)Y POPULATION 
S~bjects with VCFS, DGS, CTFA, the CHARGE association and those with cardiac defects 
associated with facial dysmorphism or palatal abnormalities will be identified from the Birth 
Defects Registry of W A. Further information concerning these patients will be obtained from 
medical records at Princess Margaret Hospitai(PMH), the Cardiology and Genetic Departments 
atPMH. 
Subjects with familial CHD or specific cardiac defects of obstruct!ve lesions of the left and right 
side of the heart will be identified from the Cardiology Department Records. 
2. DATA SHEE.T 
A request to access information from the Birth Defects Registry has been submitted. The 
project has been approved by the cardiologists at PMH. It is assumed that most of the patients 
will have consulted the Geneticists or Cardiologists at PMH. Where this is not the case, their 
consultant will be contacted by letter(see letter I) and a request for the patient's inclusion in the 
trial will be made. 
3. RECRUITMENT TO STUDY 
Parents will be sent information as an introduction to the trial by mail(see letter 2). They will 
then be approached by telephone and arrangements for an interview will be made. Initial work 
will involve examination of the proband for confirmation of diagnosis of the aforementioned 
syndromes. An information sheet(see attached) regarding the study will be given to the parents 
at the interview and consent(see attached) for inclusion in the study obtained. Diagnosis of the 
individual syndromes will be made according to accepted criteria(see table I). 
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4, FlJRTHER CLINICAL DATA 
For the families who fulfill the inclusion criteria, an assessment of their pedigrees will occur 
during the interview. Further examination of other affected family members maybe requested. 
Infonnation concerning possible intrauterine infections, alcohol intake, and medications that may 
have been taken during the pregnancy Will also be obtained. 
5, TESTING FOR 22qll MICRODELETIONS 
Blood samples will be obtained from the subjects and members of the families for DNA analysis. 
A FISH assay will be used to detect deletions of chromosome 22qll. Laboratory work will be 
done at the Cytogenetic State Health Laboratory . 
6. CONFIDENTIALITY AND SECURITY 
Information regarding the patients involved will be stored in the genetics Department at PMH in 
a locked room as is routine for all patients seen at PMH genetics clinics. 
7. LIMITATIONS OF STUDY 
There is a wide spectrum of clinical manifestations of these CATCH 22 disorders and it will not 
be possible to include the milder forms, for example isolated learning disorders. Parents or 
siblings of the proband however, may have milder forms of these disorders and will give an 
indication of their spectrum. 
In this study only the immediate family will be tested for deletions of chromosome 22qll. 
Extended family members who wish further information or investigation will be referred to the 
Genetics outpatient clinic. 
In summary, this study will explore the clinical and genetic aspects of the CATCH 22 disorders 
to gain infonnation on their prevalence in the community, the relationship between the clinical 
course of the disorder and the gene de!etion/s on chromosome 22 and the inheritance pattern of 
these disorders. This information will allow more accurate genetic counselling for families in the 
future. 
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TABLE 1 : CLINICAL FEATURES OF SYNDROMES ASSOCIATED WITH DELETIONS OF CHROMOSOME 22q11 
CAIU>U\C DEI1ECf FACIALADNOHMAI..JT\' 
P<iS{8,1l) IM c;,r:o;Jow s-.'1, o;:iro;u]ar 
I'NVSD n:urow p:!.lpcbrnl Ii:osur.:s 
TOF prominent n:IS.ll mol 
DORV sm:r.llmouth 
TA short philtrom 
VCFS(ll,16) VSD =: promin~-nt, circular 
TOF bro3d n=l root, long n010c 
DORV myopaU1ic facies 
PNVSD Pierre Robin Scqucnc:c 
IM flattened mal~ 
small mandible 
<::!Llr.lds, strD bi!;lliUS 
narrow palpcbrnl Ii~urcs 
CTAF(7) TOf . low set ears 
PA ln~lform~d :;~uricl~s 
~mJII mouth 
... 
short palpcbrnl fissures 
. 
ptosis, strabismus 
hypcrtelorisn1 
low n=l bridge 
CUAROE{I7,18) PDA ' choana! atresia 
VSD poorly fosmcdhclixor~ 
TO It colobomn 
DORV hypcrtelooism 
small mamlible 
DOS .. DIG~ORGE SEQUENCE 
VCFS • VELC-CARDIO-FACitU.SYNDROME 
CTAF- CONOTRUNCAL ANOMAL'{ FACE SYNDROME 
PAI..ATAI. STA1'URI•: I~NI>OCIUNI~ 
den . hypocah:cmia 
high ~rchcd hypoth}TOidislll 
vcloph:lryngcnl 
incompcte.Jcc 
clcn short hypoclllccmi:~ 
vdoph.al)'llgcal hypothyroidiSJII 
in~vmpctcncc 
high ar<:l1cd 
cleft 
hisharch~d . . 
11.'1.~3[ ~pcccl1 
cleft ~hort . 
high arched 
vdophal)11gcal 
incompctciiCC 
IM -IN'runRUI'TEO AORTIC t\RCII 
I' A .. J'ULMOllARY ATRESIA 
VSD,. VENTRICULAR SEPTAL DEFECT 
TOF=TETRALOGY OFF ALLOT 
I'S\'CIIIATUIC IMl\l~NE DMFNH.SS 
dcvdopm.:nt thymic aplasia or ,_, 
nonn<~lto hYf.opla.sia. 
...:~-.:r.;:ly inw 1' o.:lls 
delayed 
)QIJ\ing :o~bnorm:t!Tccll . 
difficulti.:s limction can occur 
ADDH 
depression 
psycllwo:s 
mild mental . o;onduetivc 
retardation 
mental . present 
~tar&lion 
DORY= DOODLE OUTLET JUG!ll. VENTRICI..S 
TA .. TRUNCUS ARTERIOSUS 
PDA =PATENT DUCTIIS ARTERJSOUS 
OTJIEit 
coloboJM 
rc:nal ab!XIml. 
hypotonia 
long fingCI'$ 
. 
mi®ph.lUus 
Q)ptorc:hidWn 
CNS n1alfomution 
DOS 
ADDH .. ATIENT!ON DEFICIT DISORDER AND liYPERACTJVJlY 
HEART DEFECTS IN FAMILI~S AND THEIR GENE ABNORMALITIES 
INFORMATION SHEET FOR PARENTS 
Many children are born with heart defects which vary in severity. Some complex defects 
cause death, others may require major heart surgery, and some are minor requiring no 
treatment. Causes of heart defects include· infections and drugs taken during the pregnancy 
and heredity, but more frequently the cause is unknown. 
At Princess Margaret Hospital the Cardiology and Genetic Departments are looking more 
closely St heart defects that may have a genetic cause. Specific heart defects that may be 
associated with other birth defects and may run in the family 3.re known to occur when 
genes are missing on human chromosome 22. 
We intend to look at all children in Western Australia with these heart defects to see if there 
are other minor birth defects that may not be obvious and assess their families for heart and 
birth defects. The study will determine how common these conditions are in W.A. and give 
us a better understanding of how they may possibly be passed on to other family members. 
The information obtained could be of great benefit to you and your family. 
If you agree to participate in the study, it will involve your family and children being seen in 
a genetic clinic at the hospital, asse',;sing the family tree and an examination to look for 
other minor birth defects. It will also require the taking of a blood sample from your child 
and possibly other family members to look at chromosome 22 for missing genes. 
All information about an individual family and thei, test results will be confidential. Refusal 
to participate in the study will in no way jeopardise your child's medical management. 
Any queries should be directed to Dr S Worthington at the genetics department at PMH, 
telephone number 340 8354. 
SHARRON WORTHINGTON 
Paediatric Registrar 
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RESEARCH & ETHICS SUU-COMilliTI'EE COVER SHEET 
TITLE OF PROJECT: 
HEART DEFECTS IN FAMILIES AND THEIR GENE ABNORMALITIES 
LAY DESCRIPTION: 
' . 
Approximately one out of every I 00 children is born with an abnormality of the heart. • There are 
many different types of heart defects with complex heart defects resulting in death of a child at a 
young age and other heart problems that maybe sufficiently minor not to interfere with the child's 
lifestyle. Many of the major heart defects are now correctable by heart surgery . Therefore there 
are now many adults who have had heart defects and who are contemplating families. The risks to 
their children and relatives of inheriting heait defects are important issues. 
Some heart defects recur in families and are sometimes associated with an abnormality of 
chromosome 22. Specifically, there are genes that are missing from part of this chromosome. 
These heart defects which may be quite complex and in some cases result in death of the child can 
also be associated with other birth defects as part of a syndrome. 
In this study, children with heart defects and some syndrom~s will be identified from the Birth 
Defects Registry and the Cardiology Department at Princess Margaret Hospital. The children and 
their families will be notified about the study by mail. They will then be approached by telephone 
to arrange an interview, during which further information about heart defects and other disorders 
that may be prese:1t in the family will be sought. Family members may need to be examined to see 
if they have subtle features of these disorders. An information sheet will be given to the parents at 
the interview and if they agree to their child entering the study a they will be asked to sign a 
Standard consent form. A blood sample will be taken from the children and possibliy other 
members of the family to look for missing ger.es on chromosome 22. 
The study will identity a group of children with specific heart defects which are associated with 
missing genes on chromosome 22. Children and parents with this chromosome abnormality have a 
high risk of giving birth to children with heart defects which may be even more severe than their 
own. The information gained form the study will enable doctors to give more accurate advice to 
people about these disorders when they are contemplating families. Questions such as how 
severely the child may be affected, the type of heart lesions that may occur, other physical 
abnormalities the child could have, how disabled the child may be, and the likelihood of having a 
'normal versus an affected child may be ansv,•ered. It may be possible to prevent these defects by 
looking for this gene abnormality in the baby during pregnancy. 
"PJsksn to the subjects and their families are the potential for discovery of physical abnormalities or 
diagnosis of a syndrome not previously recognised. Appropriate genetic counselling will be 
arranged if this occurs. 
EXPECTED DURATION OF STUDY: 
SOURCE & EXTENT OF RJNDING: 
IS THIS A GRANT APPLICATION ? 
IS THIS A MULTICENTRE STUDY? 
From Jan '94 To Jan '95 
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